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Abstract 
The Retinoblastoma gene (RB1) was the first tumor suppressor gene to be 
cloned. Its encoded protein, the Retinoblastoma protein (pRB) is a member of the 
Retinoblastoma family, which is constituted also by p107 and p130. This family plays a 
critical role in the control of the progression through the different phases of the cell 
cycle. pRB is particularly involved in the G1-to-S transition and, although its role in cell 
cycle regulation is well defined, its role in the regulation of cell death remains 
controversial. In this work, we have performed a systematic and global study of the 
Retinoblastoma family members and of the various functional domains of pRB in the 
regulation of E2F activity, cell cycle progression, DNA replication, and in the regulation 
of cell death triggered by ionizing radiation (IR). While all family members inhibited E2F 
activity and DNA replication, and accumulated cells in G0/G1 in the short-term, pRB 
was the only member of the family that inhibited IR-induced cell death and arrested 
cells in the G0/G1 cell cycle phase in the long-term. We have found a strong 
correlation between the capacity of pRB to induce a long-term arrest of the cell cycle 
and its capacity to inhibit cell death, suggesting that a sustained arrest of the cell cycle 
in G0/G1 is necessary and sufficient to inhibit cell death caused by DNA damage. 
These data suggest that pRB may not play a direct role in the regulation of cell death 
induced by DNA damage and that cell survival might be the consequence of its main 
function, the arrest of the cell cycle until DNA damage has been eliminated. We have 
forced the expression of various domains of pRB and the results obtained strongly 
suggest that a correct folding of pRB, integrating its small pocket and carboxyl terminus 
into the large pocket, is critically required to efficiently inhibit IR-induced cell death and 
to block cell cycle progression in the long-term. Finally, we have created in-silico a 3-
dimensional model of full-length pRB that shows the presence of an amino acid from 
the carboxyl terminus (R798) in the soil of the pocket, next to an amino acid from the 
A-domain (K530). The analysis of the conformational changes induced by inactivating 
mutations in the A- or in the B-domain showed that the carboxyl terminus was more 
severely affected than the small pocket. The in-silico analysis therefore supports the 
notion that the functional pRB large pocket is the result of the structural integration of 
the small pocket and the carboxyl terminus.  

Resumen 
El gen Retinoblastoma (RB1) fue el primer gen supresor de tumores clonado y 
codifica la proteína Retinoblastoma (pRB). Esta proteína es el miembro fundador de la 
familia Retinoblastoma, que también está constituida por p107 y p130. Esta familia juega 
un papel crítico en el control de la progresión a través de las diferentes fases del ciclo 
celular. pRB está particularmente implicado en la transición de G1 a S y, aunque su papel 
en la regulación del ciclo celular está bien definido, su papel en la regulación de la muerte 
celular sigue siendo controvertida. En este trabajo hemos realizado un estudio sistemático 
y global de los miembros de la familia de Retinoblastoma y de los diferentes dominios 
funcionales de pRB en la regulación de la actividad de E2F, la progresión del ciclo celular, 
la replicación del ADN y en la regulación de la muerte celular provocada por la radiación 
ionizante (IR). Mientras que todos los miembros de la familia Retinoblastoma inhibieron la 
actividad de E2F y la replicación del ADN, y favorecieron la acumulación de las células en 
G0/G1 a corto plazo, pRB fue el único miembro de la familia que inhibió la muerte celular 
inducida por IR y detuvo las células en la fase G0/G1 a largo plazo. Hemos encontrado 
una fuerte correlación entre la capacidad de pRB para inducir una detención a largo plazo 
del ciclo celular y su capacidad para inhibir la muerte celular, lo que sugiere que una 
detención sostenida del ciclo celular en G0/G1 es necesaria y suficiente para inhibir la 
muerte celular causada por daño del ADN. Estos datos sugieren que pRB no desempeña 
un papel directo en la regulación de la muerte celular inducida por daño del ADN y que la 
supervivencia celular sería la consecuencia de su función principal, la detención del ciclo 
celular hasta que el daño del ADN ha sido eliminado. Hemos forzado la expresión de 
diversos dominios de pRB y los resultados obtenidos sugieren fuertemente que un 
plegamiento de pRB que permita la integración del dominio llamado bolsillo pequeño con 
la región carboxilo terminal es esencial para inhibir eficientemente la muerte celular 
inducida por IR y para bloquear la progresión del ciclo celular a largo plazo. Por último, 
hemos creado in silico un modelo tridimensional de pRB completa que muestra la 
presencia de un aminoácido del extremo carboxilo (R798) en el suelo del bolsillo, junto a 
un aminoácido del dominio A (K530). El análisis de los cambios conformacionales 
inducidos por mutaciones inactivadoras en el dominio A o en el dominio B mostró que el 
extremo carboxilo estaba más gravemente afectado que el bolsillo pequeño. El análisis in 
silico por lo tanto apoya la noción de que el denominado bolsillo grande de pRB es el 
resultado de la integración estructural del bolsillo pequeño con el dominio carboxilo 
terminal. En conjunto, nuestros datos sugieren que esta integración estructural podría dar 
lugar a la formación de un dominio funcional en pRB necesario para la parada sostenida 
del ciclo celular y la inhibición de muerte que no estaría presente en p107 y p130. 
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 Abbreviations 
 
ATM Ataxia telangiectasia-mutated protein kinase 
ATR ATM and Rad3-related protein kinase 
Bak Bcl-2 homologous antagonist/killer protein 
Bax Bcl-2-associated X protein 
BRCA1 Breast cancer growth suppressor protein 1 
BRG1 Brahma-related gene-1 
c-Abl Abelson leukemia oncogene cellular homolog 
Caspase Cysteine proteases with aspartate specificity 
CD95 Cluster of differentiation 95 
CD95L Cluster of differentiation 95 ligand 
CDKs Cyclin dependent kinases 
Chk Checkpoint kinase 
CHX Cycloheximide 
CIP/KIP family CDK-interacting protein/Kinase-inhibitory protein family 
CKIs Cyclin-dependent kinase inhibitors 
C-ter Carboxyl terminus 
DAPI 4',6-diamidino-2-phenylindole 
DDR DNA damage response 
DP DRTF1-polypeptide 
DRTF1 Database of Rice Transcription Factor-1 
E1A Adenovirus early region 1A 
E2F E2 transcription factor 
E7 Human papilloma virus-16 early region 7 
EDTA Ethylenediaminetetraacetic acid 
EdU 5-Ethynyl-2´-deoxyuridine 
Fas First Apoptotic Signal 
FasL First Apoptotic Signal Ligand 
G1 phase Gap phase 1 
G2 phase Gap phase 2 
GFP Green fluorescent protein 
HA Hemagglutinin 
HDAC Histone deacetylases 
HDM2 Human double minute 2 
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 HU Hydroxyurea 
INK4 family Inhibitor of CDK4 family 
IR Ionizing radiation 
M phase Mitosis phase 
Mad2 Mitotic arrest deficient 2 
Mdm2 Murine double minute 2 
MEFs Mouse embryonic fibroblasts 
Mim Mimosine 
Noc Nocodazole 
PBS Phosphate-buffered saline 
PMSF Phenylmethylsulphonyl fluoride 
PNUTS Phosphatase Nuclear Targeting Subunit 
pp32 Phosphoprotein 32 
pRB Retinoblastoma protein 
RB NPC pRB mutated in N-terminus, pocket and C-terminus 
RB C-ter pRB carboxyl terminus 
RB SE pRB carboxyl terminus from the SspI site to the end 
RB ΔI Retinoblastoma protein truncated in ICE-site 
RB-MI Retinoblastoma protein mutated in ICE-site 
RB-PMS Phosphorylation site mutated Retinoblastoma protein 
S phase Synthesis phase 
SDS Sodium dodecyl sulphate 
SV40 Simian Virus 40 
TFIIH Transcription factor II Human 
TNF family Tumor necrosis factor family 
Tub Tubulin 
WCE  Whole cell extract buffer 
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1. Retinoblastoma family and cell cycle control 
1.1. Cell cycle overview 
The cell cycle is a highly-controlled series of events that ensures correct 
replication of the DNA during S phase and guarantees equal distribution of identical 
chromosome copies into two daughter cells during M phase (Heichman and Roberts 
1994; Wuarin and Nurse 1996). It is possible to identify separated phases in the cell 
cycle: 1) The Gap phase 1 (G1 phase) in which cells spend most of the time and 
prepare themselves for DNA replication; 2) the Synthesis phase (or S phase) in which 
cells replicate their DNA; the Gap phase 2 (G2 phase) in which cells duplicate all the 
other cellular components and resumes its growth in preparation for division; and 4) the 
mitosis phase (or M phase) which consists in the physical separation of the genetic 
material and the cellular components (the cytokinesis). 
The unidirectional progression along the different phases of the cell cycle is 
strictly regulated by the “cell cycle control system” or “checkpoint control”. Each 
checkpoint serves as a potential point in the cell cycle that ensures the progression to 
the next phase only if favorable conditions are met. 
The G1 checkpoint (also known as Restriction checkpoint) regulates the entry 
through the cell cycle. Depending internal and/or external condition, the Restriction 
point can delay G1 phase, lead cells in a quiescent state (G0 phase) or allow cell cycle 
progression, promoting the transition from G1 to S. The G2/M checkpoint, also known 
as the DNA damage checkpoint, ensures that the cell has correctly completed the 
replication of the DNA during the S phase and properly achieves all the necessary 
changes in G2 phases. Accordingly, the G2/M checkpoint monitors if the cell is ready 
to divide. Finally, the Metaphase checkpoint controls the metaphase-to-anaphase 
transition in Mitosis, ensuring sister chromatid separation and driving for completion of 
Mitosis and Cytokinesis. The existence of an intra-S phase checkpoint, involved mostly 
in DNA damage response, has been also hypothesized (Nyberg et al. 2002; Bartek et 
al. 2004; Zhu et al. 2004). Once the cell splits into its two daughter cells, they enter 
again in G1 and the cycle continues. 
The importance of a correct control of cell cycle progression is underlined by the 
observation that tumor cells typically acquire alterations to genes whose products are 
involved in cell cycle regulation. Not by chance, uncontrolled cell proliferation is 
considered a hallmark of cancer (Sherr 1996; Hanahan and Weinberg 2000). A great 
number of proteins are involved in the molecular mechanisms that control cell cycle 
progression and the Retinoblastoma family of proteins plays a key role in regulating the 
transition through the different phases of the cell cycle. 
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1.2. The Retinoblastoma family of proteins: pRB, p107 and p130 
The Retinoblastoma family of proteins, or RB family, has a collective role in cell 
cycle control and tumor suppression. This family of proteins, known also as the pocket 
proteins, includes three members: Retinoblastoma protein (pRB), p107 and p130 
(Cobrinik 2005; Henley and Dick 2012). Although the three proteins show high 
homology, p107 and p130 share more structural and functional similarity than pRB. 
The most highly conserved region, the so-called “small pocket”, is characterized 
by two distinct functional domains (A and B domain), separated by a flexible spacer 
(Classon and Harlow 2002). p107 and p130 contain a longer spacer region than pRB, 
that allows them to stably interact with proteins involved in cell cycle regulation, such 
as the Cyclin-dependent kinase complexes (Zhu et al. 1995; Lacy and Whyte 1997; 
Woo et al. 1997). Furthermore, they present an insertion in the B domain of the small 
pocket sensitive to phosphorylation and that, at least for p130, could be useful to 
maintain its stability (Litovchick et al. 2004). 
The small pocket is the minimal region capable of interacting with proteins that 
possess the LXCXE peptide motif such as viral oncoproteins (including adenovirus 
E1A, simian virus 40 tumor antigen, and Human Papillomavirus E7 protein), D-type 
cyclins, and proteins with chromatin-modifying activity, like histone deacetylase, 
HDACs (Ludlow and Skuse 1995) (Dowdy et al. 1993; Ewen et al. 1993) (Brehm et al. 
1998). 
The combination of the small pocket and the carboxyl terminal domain is called 
the “large pocket”, that is the minimal growth suppression domain found in RB family 
proteins (Qin et al. 1992; Sellers et al. 1995). An intact large pocket is necessary and 
sufficient for the interaction and inhibition of E2F family of transcription factors (Hiebert 
et al. 1992; Qin et al. 1992; Flemington et al. 1993; Helin et al. 1993). 
E2F family members regulate the expression of genes involved in cell cycle 
progression. The inhibition of their transcriptional transactivation activity through their 
binding to the pocket proteins, emphasizes the role of pRB, p107 and p130 in cell cycle 
progression’s control (Dyson 1998; Dimova and Dyson 2005). Furthermore, the 
disruption of this interaction by viral oncoproteins, reinforces the relevance of the 
pocket proteins in avoiding cellular transformation (Whyte et al. 1988). 
The carboxyl terminal region of pRB harbors two domains that are absent from 
p107 and p130: an E2F1-specific binding site, involved in regulation of apoptosis (Dick 
and Dyson 2003), and a short peptide region able to interact with Cyclin/CDKs 
complexes or Protein Phosphatase 1 (PP1) (Dunaief et al. 2002). In contrast, the 
amino terminal region of p107 and p130 contain a kinase inhibitor domain that is 
absent from pRB (Woo et al. 1997). 
   Introduction 
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The ability of pRB, p107 and p130 to employ their different functional domains, 
allow these proteins to interact and regulate a great number of binding partners and to 
properly perform their cellular functions. 
 
1.3. Retinoblastoma family in cell cycle control 
The importance of the role of Retinoblastoma family proteins in cell cycle control 
was perceived since Chellappan and colleges’ description of E2F transcription factors 
as a cellular target of Retinoblastoma protein (Chellappan et al. 1991), and previous 
finding of the interaction between virus oncoproteins and pocket proteins (Ludlow and 
Skuse 1995). 
Pocket proteins regulate the E2F family of transcription factors. 
Although the levels of pRB, p107 and p130 changed along the cell cycle, all the 
three pocket proteins have a direct role in cell cycle regulation (Henley and Dick 2012). 
They have in common the ability to bind, and regulate, E2F transcription factors 
(Chellappan et al. 1991; Hiebert et al. 1992; Flemington et al. 1993; Helin et al. 1993; 
Dyson 1998). 
To date, eight different members of the E2F family, and two DP binding partners 
(DP1 and DP2), have been described. E2F1, E2F2 and E2F3a have a more potent 
transcriptional activity than the other members of the family; for this reason, they are 
classified as the activator E2Fs. In contrast, E2F3b, E2F4 and E2F5 are the repressor 
E2Fs because of their limited activation potential. Furthermore, E2F4 and E2F5 lack a 
functional nuclear localization signal and they rely on pocket proteins for their 
translocation to the nucleus. E2F6 does not have a transactivation domain or a pocket 
proteins binding domain. It regulates cell cycle in a pocket proteins’ independent 
manner, possibly through its association to proteins of the Polycomb group. Less is 
known about the mechanism of action of E2F7 and E2F8 (Dimova and Dyson 2005).  
The high expression of p130 in resting cells (G0 phase of the cell cycle) is 
considered a reliable marker of quiescence, in which p130 complexes mainly with 
E2F4. Although p107 is almost undetectable, pRB expression is present at lower level 
than p130 and preferentially binds to repressor E2F3b (Moberg et al. 1996; Hurford et 
al. 1997). To ensure the maintenance of the quiescent state, pRB also represses t-
RNA and r-RNA expression in G0, while p130 represses r-RNA transcription (Hannan 
et al. 2000). 
Following appropriate stimuli, and according with optimal external condition 
detected by the G1 checkpoint, cells can progress to the next phase of the cell cycle 
(G1 phase), in which the three pocket proteins are detectable and interact with E2F 
transcription factors. 
Introduction   
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In early G1, the most abundant pocket protein/E2F complex present is composed 
by p130 and E2F4. The inhibition of E2F responsive genes mediated by p130 is 
maintained until mid-G1 phase, when it is replaced by p107 at E2F responsive 
promoters, until late G1 (Moberg et al. 1996; Takahashi et al. 2000; Wells et al. 2000). 
At this point of the cell cycle, pRB increases its levels and associates with activator 
E2Fs, inhibiting their transactivation capacity (Hiebert et al. 1992; Flemington et al. 
1993; Helin et al. 1993). 
E2F responsive genes include mostly genes whose expression is required for cell 
cycle progression from G1-to-S phase, including cell cycle regulators, components of 
the replication machinery and enzymes involved in nucleotide biosynthesis. Although it 
is not known how pocket protein/E2F complexes selectively interact with specific 
promoters, it is widely accepted that pRB, p107 and p130 negatively regulate the cell 
cycle mainly through the inhibition of E2F factors (Dyson 1998; Henley and Dick 2012). 
This notion is further supported by the necessity of some viral oncoproteins to disrupt 
pocket protein/E2F complexes to induce expression of E2F responsive genes and 
cellular transformation (Whyte et al. 1988). 
The ability of the pocket proteins to bind E2F transcription factors depends on 
their phosphorylation state. 
The main kinases involved in pocket proteins phosphorylation are the cyclin-dependent 
Kinases, or CDKs. Cyclins are regulatory subunits required for CDKs activation, but the 
additional interaction with the CDK-activating kinase (CAT) is needed also for the full 
activation of the complex. Although the levels of CDKs are normally constant 
throughout the cell cycle, the expression of the different cyclins changes along the cell 
cycle: D-type cyclins are expressed in late G1 and interact with CDK4 and 6; Cyclin E 
is present during G1-to-S transition and complexes with CDK2; CDK2 and CDK1 can 
also form complexes with Cyclin A early in S phase to promote DNA replication; and 
Cyclin B is expressed in Mitosis and binds and actives CDK1(Malumbres and Barbacid 
2005). 
Not surprisingly, cells present different levels of control of Cyclin-dependent 
kinase activity to ensure correct progression through the different phases of the cell 
cycle. One of the best characterized mechanisms involves their association with cyclin-
dependent kinase inhibitors (CKIs). There are two families of CKIs: the CIP/KIP family, 
which consists of p21, p27 and p57, and the INK4 family, which consists of p16, p15, 
p18 and p19. The main difference between these two families of inhibitors is that 
CIP/KIP family members can inhibit any Cyclin/CDK complex that is found in G1, 
whereas INK4 proteins only block the kinase activity of Cyclin D-bound CDK4 and 
CDK6 (Sherr and Roberts 1999; Vidal and Koff 2000; Besson et al. 2008). 
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In addition, p107 and p130 contain a dedicated domain for CDK inhibition that is 
absent from pRB (De Luca et al. 1997; Woo et al. 1997). However, pRB can also inhibit 
CDK activity through its capacity to interfere with p27 proteolysis in G1 (Ji et al. 2004; 
Binne et al. 2007). 
The G1-to-S transition requires the correct activation of specific Cyclin/CDKs 
complexes and the sequential phosphorylation of the pocket proteins by them to 
release E2F factors and activate the expression of E2F responsive genes. Pocket 
proteins’ phosphorylation starts at late G1 by active Cyclin D/CDK4 or 6 kinase 
complex (Dowdy et al. 1993). The release of activator E2Fs allows the expression of 
Cyclin E and the following formation of active complex Cyclin E/CDK2. At this point, the 
most import mechanism to avoid uncontrolled entry in S phase is mediated by p27. 
Once DNA replication has been started, the activation of Cyclin E/CDK2 induces 
phosphorylation and subsequent degradation of p27 (Ji et al. 2004; Binne et al. 2007). 
This event allows full activation of Cyclin E/CDK2, which completes pocket proteins’ 
phosphorylation and totally disrupts their interaction with E2F family members (Sherr 
and Roberts 1999; Malumbres and Barbacid 2005). Sequential phosphorylation of the 
pocket proteins is necessary because phosphorylation mediated by Cyclin D/CDK4 or 
6 is not enough to complete their inactivation and because CDK2 cannot bind 
unphosphorylated proteins as substrate (Lundberg and Weinberg 1998). 
To avoid genome instability that may result in cell transformation, once cells start 
the replication of the DNA, the cell cycle progresses until cell division is completed. 
Release of E2F transcription factors from pocket proteins coincides with the “point of 
no return” in which cells are obligated to complete the rest of the cell cycle (Yao et al. 
2008). Again, pocket proteins play an important role in G1-to-S progression’s control, 
avoiding reverse direction of it. 
Recently Cappell et al. propose the idea of a “window of reversibility” in which 
cells can return to a quiescent state and that the inactivation of the anaphase-
promoting complex/cyclosome (APCCdh1) has the necessary characteristics to be the 
point of no return for cell-cycle entry, in a pocket proteins independent way (Cappell et 
al. 2016). 
Pocket proteins have also a role in Mitosis.  
Overexpression of some mitotic checkpoint genes (Emi1 and Mad2) has been 
observed in pRB deficient cells. The finding that these genes are target of E2F 
transcription factors, suggests a possible role of pocket proteins in Mitosis (Sotillo et al. 
2007; Weaver et al. 2007). Besides these E2F-dependent effects, deficiency of all the 
three pocket proteins results in mitotic errors, due to a defective chromosome structure 
in pericentromeric region (Gonzalo et al. 2005; Manning et al. 2010). 
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At the end of Mitosis, specific phosphatases induce pocket proteins’ 
dephosphorylation and consequently activation of their growth suppression functions, 
thus leading cells to correctly complete cell division into two daughter cells (Ludlow et 
al. 1993). Finally, cells enter again in G1 phase and the cycle can proceed. 
 
1.4. Retinoblastoma family in DNA damage response. 
Alterations in DNA damage response (DDR) pathways are often associated with 
tumor transformation (Sancar et al. 2004). DNA damage response is a highly-
controlled process that arrests cell cycle progression when an injury could affect DNA 
integrity. The activation of cell cycle checkpoints avoids progression to the next phase 
of the cell cycle and allows the activation of the DNA repair system: if the damage is 
repaired, cell cycle can be resumed. Otherwise, cells undergo programmed cell death, 
or apoptosis (Weinert 1998a; Weinert 1998b; Nyberg et al. 2002).  
DNA double-strand brakes recruit and activate ATM and ATR kinases, which, in 
turn, activate cell cycle checkpoint kinase 1 and 2 (Chk1 and Chk2). Phosphorylation of 
p53 by Chk1 and 2 decreases its binding to the E3-Ubiquitin ligase HDM2 (Mdm2 in 
mice) and therefore reduce p53 degradation. The increase of p53 levels promotes its 
tetramerization and subsequent translocation to the nucleus, where it induces 
expression of the CIP/KIP family member p21. Consequently, p21 inhibits kinase 
activity of the specific Cyclin/CDKs complexes present at the time of the injury, and 
prevents pocket proteins’ phosphorylation. Pocket proteins acquire again cell growth 
suppression’s function, preventing progression of the cell cycle (Brugarolas et al. 
1999). 
In addition, p21 can be induced also through p53-independent mechanisms 
(Macleod et al. 1995; Galanos et al. 2016). Furthermore, Chk1 can also inhibits activity 
of Cdc25 family members (phosphatases that activate Cyclin-dependent kinases of M 
and S phase) in response to DNA damaging agents (Xiao et al. 2003). 
In summary, DDR actives a controlled sequence of molecular events that inhibit 
the activity of Cyclin/CDKs complexes, restore the cell growth suppression function of 
pocket proteins and promote a pause in the cell cycle. If the DNA repair system fixes 
the injury, cells restart their progression through the cell cycle. Conversely, if the 
damage cannot be repaired, cells will activate their suicide (Cerqueira et al. 2009; Yata 
and Esashi 2009). 
There is also evidence of a regulatory function of p107 and p130 in DDR, but 
their contribution has been studied in much less detail (Jackson et al. 2005). 
Nevertheless, it seems plausible that the contribution of pocket proteins to DDR could 
mediate, at least in part, their capacity to suppress cellular transformation. 
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2. Focusing in pRB: pRB as a multifunctional protein 
2.1. From a target of viral oncoproteins to a cell cycle regulator 
In human, the tumor suppressor Retinoblastoma protein (pRB) is the product of 
the RB1 gene, located in chromosome 13q14. It was identified as a gene whose loss is 
responsible for the predisposition to retinoblastoma and osteosarcoma (Friend et al. 
1986) and it was the first tumor suppressor gene to be cloned (Fung et al. 1987; Lee et 
al. 1987).  
Retinoblastoma protein was identified as an important target of viral 
oncoproteins. In 1988, for the first time, it was described that simian virus 40 (SV40) 
large tumor antigen formed a specific complex with the product of the retinoblastoma 
susceptibility gene (DeCaprio et al. 1988). In the same year, the association with 
another oncoprotein, the adenovirus E1A protein, was characterized (Whyte et al. 
1988) and the first evidence of pRB tumor suppression’s capacity was obtained, 
analyzing the suppression of the neoplastic phenotype mediated by pRB in human 
cancer cells (Huang et al. 1988). The Human papilloma virus-16 E7 oncoprotein was 
also found to bind to Retinoblastoma protein (Dyson et al. 1989; Munger et al. 1989; 
Lee et al. 1998). Of note, the region of interaction of these viral oncoproteins in pRB 
sequence is a common site of mutations in human tumor cells (Hu et al. 1990; Huang 
et al. 1990). Further studies identified amino acids 379-792 as the minimal binding 
domain for these viral oncoproteins in pRB (Kaelin et al. 1990). These studies showed 
for the first time a physical link between an oncoprotein and a tumor suppressor 
protein.  
To explain the growth suppression properties of pRB, a model suggesting a role 
for pRB in cell cycle regulation was proposed (DeCaprio et al. 1989). The new concept 
of pRB as a cell cycle regulator protein, encouraged additional research along this line, 
and, in fact, Chellappan and coworkers described in 1991 that the E2F transcription 
factor was a cellular target for pRB (Chellappan et al. 1991). This work also confirmed 
the cell cycle-dependent phosphorylation of pRB. The role of pRB was further clarified 
that year by showing that RB acted in a specific point of the G1 phase of the cell cycle; 
exogenous pRB failed to inhibit DNA replication in cells synchronized in late G1 or in 
G1/S, suggesting that pRB does not inhibit DNA synthesis once DNA replication is 
initiated (Goodrich et al. 1991). 
The evidence that viral oncoproteins shared the ability to disrupt the interaction 
between pRB and E2F proteins (Chellappan et al. 1992), reinforced the importance of 
pRB in cell cycle regulation. E1A, the SV40 large tumor antigen and E7 disrupted 
pRB/E2F interaction and stimulated a proliferative state. The consequent loss of cell 
cycle control may be the initiation of the oncogenic process in a manner analogous to 
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the inactivating mutations founded in the RB1 gene. Not by chance, analysis of human 
cervical carcinoma cell lines expressing E7 protein or carrying RB1 mutations revealed 
no formation of pRB/E2F complexes (Chellappan et al. 1992). 
The demonstration that pRB was a negative regulator of E2F transcription activity 
(Hiebert et al. 1992; Flemington et al. 1993; Helin et al. 1993) and a target of 
phosphorylation mediated by Cyclin/CDK complexes (Hinds et al. 1992; Dowdy et al. 
1993; Ewen et al. 1993) further supported the notion that pRB was involved in cell 
cycle control. 
The study of non-functional and deletion mutants of RB1 opened a new 
understanding of the protein’s functions, focusing on the relevance of a proper 
structure to allow correct performance of the biological properties pRB (Templeton et 
al. 1991; Qian et al. 1992). The minimal growth suppression domain of the protein 
(Qian et al. 1992) and the region necessary for its interaction with E2F proteins 
(Hiebert 1993) were identified soon. Furthermore, an amino-terminal deletion of pRB 
(RB 379-928) showed enhanced growth suppression function (Xu et al. 1994). A 
single-point mutation in E2F1 sequence was found that destroyed its interaction with 
pRB and that increased cells replication (Shan et al. 1996). 
In contrast with the idea that a stable pRB/E2F interaction was necessary and 
sufficient for cell growth’s inhibition, Sellers and colleagues suggested that this 
interaction was not required for pRB to activate transcription, promote differentiation 
and suppress tumor cells growth (Sellers et al. 1998). Moreover, although a low-
penetrance pRB mutant, RB 661W (Onadim et al. 1992; Lohmann et al. 1994), was 
defective in E2F binding (or at least less efficient than the wild-type protein), it 
suppressed cell growth (Whitaker et al. 1998). In this regard, pRB can also inhibit G1-
to-S progression in an E2F-independent way, by increasing p27 expression (Alexander 
and Hinds 2001; Ji et al. 2004); inducing PML nuclear bodies formation (and inhibiting 
their effect on cell proliferation, differentiation and survival) (Fang et al. 2002); 
suppressing pro-proliferative Ras signaling (Lee et al. 1999); or augmenting expression 
of differentiation-associated genes (Sellers et al. 1998; Thomas et al. 2001). 
The knowledge of the role of pRB in cell cycle control has become more detailed 
and complex since its discovery. The characterization of the other two members of the 
RB family, p107 (Ewen et al. 1991) and p130 (Baldi et al. 1996), and the overlapping 
functions of these proteins in important biological processes (Cobrinik et al. 1996; Lee 
et al. 1996; Hurford et al. 1997; Classon et al. 2000; Sage et al. 2000), are just some of 
the features that make the study of the Retinoblastoma protein fascinating. 
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2.2. pRB as a scaffold: the matchmaker hypothesis 
The three-dimensional structure of the small pocket (Lee et al. 1998) suggests 
that pRB can simultaneously bind to more than one target, and that only a correct 
conformation of the protein can facilitate optimal interactions with its different partners 
and proper fulfillment of the different biological functions. To date, more than 150 
different partners of pRB have been identified and this number could increase year 
after year (Morris and Dyson 2001; Goodrich 2006; Dyson 2016). The ability of pRB to 
interact and regulate such a great number of proteins raises the question of how many 
different functions might be able to perform this protein. 
It was described that the carboxyl-terminal end of pRB regulates nuclear activity 
of the c-Abl tyrosine kinase, suggesting a “matchmaker function” of pRB (Welch and 
Wang 1993; Welch and Wang 1995a). pRB was detected in a trimeric complex with 
E2F and c-Abl and, supporting the matchmaker hypothesis, it was proposed that the 
biological activity of pRB not only depends on the inhibition of its targets, but also on its 
ability to properly assemble specific protein complexes (Welch and Wang 1995b). In 
fact, simultaneous overexpression in a pRB deficient cell line of full length wild-type 
pRB and a mutated carboxyl-terminal fragment of pRB (RB SEΔ), that loss the amino 
acids involved in E2F binding but not the ability to inhibit the kinase activity of c-Abl, 
showed a dominant-negative function of RB SEΔ over pRB function in cell growth 
inhibition (Welch and Wang 1995b). 
Retinoblastoma protein also forms a complex with the ATP-dependent helicase 
BRG1 (Khavari et al. 1993; Dunaief et al. 1994). This interaction cooperates in the 
induction of cell cycle arrest (Dunaief et al. 1994; Strober et al. 1996; Strobeck et al. 
2000; Zhang and Dean 2001) and in the repression of E2F1 (Trouche et al. 1997). The 
relevance of this interaction was confirmed by the discovery in human cancer cell lines 
of BRG1 mutations that destroy pRB capacity to arrest the cell cycle (Bartlett et al. 
2011). In the context of chromatin remodeling, pRB also recruits histone deacetylase 
proteins (Brehm et al. 1998). The interaction between the small pocket of pRB and the 
LXCXE motif of HDACs provided a plausible mechanism for the active repression of 
E2F responsive genes by pRB (Brehm et al. 1998; Magnaghi-Jaulin et al. 1998; Dahiya 
et al. 2000). 
 
2.3. pRB in embryo development 
Before starting the description of pRB as a tumor suppressor protein and its 
functions in cell death, it is important to mention its functions during embryonic 
development. In fact, although pRb is ubiquitously expressed in adult mouse tissues, 
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its expression is temporally and spatially controlled during embryogenesis (Classon 
and Harlow 2002). 
In 1992, three independent groups reported a mouse strain in which one allele of 
Rb1 was disrupted. Contrary to human patients, Rb1+/- mice showed no predisposition 
to develop retinoblastoma tumors, but some mice displayed pituitary tumor. In contrast, 
Rb1-/- embryos died between days 14 and 15 of gestation and showed defects in 
hematopoiesis and neurogenesis associated to strong E2F-dependent cell death, both 
in central and in peripheral nervous system (Clarke et al. 1992; Jacks et al. 1992; Lee 
et al. 1992). These observations strongly suggested that pRB played a critical anti-
apoptotic role during embryonic development and prompted the generation of Rb1 and 
E2fs double knock-out mice in which loss of Rb1 with E2f1 decreased cell death only in 
the central nervous system, whereas loss of Rb1 and E2f3-/- diminished cell death only 
in the peripheral nervous system. The defects in DNA replication and apoptosis found 
in Rb1-/- embryos were inhibited only partially in Rb1-/-;E2f2-/- embryos (Saavedra et al. 
2002).  
Regarding the major repressive E2F family member, E2f4, its loss suppressed 
the development of both pituitary and thyroid tumors in pRb heterozygous mice, and 
reduced alteration in both gene expression and proliferation observed in pRb deficient 
cells. In Rb1-/-;E2f4-/- mice, p107 and p130 inhibit the activator members of E2F, 
suggesting that these pocket proteins compensate the absence of pRB to suppress 
tumor formation (Lee et al. 2002). To support this hypothesis, Dannenberg and co-
authors generated chimeric mice with loss of the different pocket proteins genes, and 
they confirmed that pRb/p107 or pRb/p130 deficient mice were highly prone to develop 
tumors in different tissues (Dannenberg et al. 2004). 
Remarkably, the expression of an E2f binding-deficient Rb protein, analogous to 
low-penetrance human pRB mutant RB 661W, partially rescued the developmental 
defects in Rb nullizygous mice (Sun et al. 2006). 
All these data underline the complexity of pRB function in development. The 
engineering of conditional pRb-KO mice allowed a better understanding of the role of 
pRb in tissue differentiation. The affected tissues seemed to try a differentiation 
program in the absence of pRb, as determined by the induction of early lineage-
specific markers, but failed to reach correct terminal differentiation (Goodrich 2006). 
These observations were also confirmed in mouse embryonic fibroblasts (MEFs) in 
vitro: cells established from pRb-deficient mice embryos showed defect in myogenesis 
and adipogenesis as well as in limb development (Cobrinik et al. 1996), confirming the 
importance of pRB in proliferation, apoptosis and differentiation during development. 
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3. pRB is a tumor suppressor protein 
3.1. pRB pathway in cancer 
Uncontrolled cell proliferation is a hallmark of cancer (Sherr 1996; Kaelin 1997; 
Hanahan and Weinberg 2000) and cell cycle regulators are frequently mutated in 
human cancers (Malumbres and Barbacid 2001). Supporting Knudson’s “Two-hit 
hypothesis”, (Knudson 1971; Knudson et al. 1975), germline mutations of the RB1 
gene causes the highly penetrant hereditary retinoblastoma, as the result of bi-allelic 
loss of this gene in embryonic retinoblasts (Cavenee et al. 1983; Dunn et al. 1988). 
RB1 was found mutated later in various cancer types. In addition, although many 
human tumors retain wild-type RB1, they present mutations that indirectly affect pRB 
activity as a “master regulator” of cell cycle progression (Kaelin 1997; Malumbres and 
Barbacid 2001; Classon and Harlow 2002; Zhu et al. 2015). Thus, in the multistep 
nature of cancer (Vogelstein and Kinzler 1993), inactivation of cell cycle control 
systems is necessary for tumor transformation and underscores the importance of the 
maintenance of these systems for cancer prevention. 
Amplification of CCND1 or CDK4, translocation of CDK6 and deletion of INK4 
family proteins-encoding genes (CDKN2) or RB1 deletion are the most common 
chromosomal alterations observed in human cancers. Furthermore, methylation of 
CDKN2A or RB1 promoters, and their consequent inactivation, are additional 
alterations identified in cell cycle regulators in human cancers. (Sherr 1996; Kaelin 
1997; Malumbres and Barbacid 2001; Dyson 2016). Together, these findings strongly 
support the notion that loss of cell cycle control, in which pRB plays a key role, is a 
crucial step in cell transformation. 
More evidences of pRB role as a tumor suppressor protein are described with 
respect to p107 and p130. However, it was suggested tissue-specific tumor 
suppression activity of both p107 and p130, by the observation that pRb/p107-  or 
pRb/p130-deficient mice are more susceptible to tumor development than pRb null 
mice (Dannenberg et al. 2004). Moreover, p107 presents tumor suppression ability in 
pRb-deficient epidermis (Lara et al. 2008), while p130 could be involved in 
retinoblastoma tumor development (Tosi et al. 2005). 
Thus, all these observations strongly suggest tumor suppressor activity of pocket 
proteins. 
 
3.2. pRB in DNA damage response 
As mentioned above, the DNA damage response induces a pause on cell cycle 
progression if any of the cell cycle checkpoints detects an injury on DNA. pRB plays a 
fundamental role in cell cycle arrest induced by DNA damage, revealing the tumor 
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suppressor role of this protein. Defects in G1 phase arrest in response to gamma-
irradiation observed in Rb1-/- MEFs underline the importance of pRb in DNA damage-
induced cell cycle arrest (Harrington et al. 1998). Moreover, pRb is also 
dephosphorylated and therefore activated during S-phase to inhibit cell cycle 
progression in MEFs treated with various genotoxic stimuli to inhibit cell cycle 
progression (Knudsen et al. 2000). Furthermore, human tumor cell lines with defective 
cell cycle-dependent activation of pRB (like the U2OS osteosarcoma cell line) also 
appear to be defective for pRB activation in response to DNA damage, displaying a 
phenotypic behavior similar to pRB-defective cells (Broceno et al. 2002). In this regard, 
pRB controls both replication and re-replication (Barbie et al. 2004). In fact, pRB is 
recruited to focal replication foci after DNA damage to block early firing of replication 
origins in S phase (Blow and Hodgson 2002; Avni et al. 2003).  
Defects in pRB pathway regulation also increase the levels of the E2F’s target 
Mad2, a protein whose overexpression is associated with mitotic defects that lead to 
aneuploidy and tumorigenesis (Hernando et al. 2004; Sotillo et al. 2007). These 
findings reinforce the idea that the pRB pathway plays a critical role in G2 checkpoint 
control after DNA damage. 
Finally, pRB is a required mediator of the interaction between Topoisomerase II-β 
and BRCA1 for the correct activation of their DNA repair function in cells treated with 
the cytotoxic anticancer drug Etoposide (Xiao and Goodrich 2005). These results 
confirm the role of pRB in DNA damage response and tumor suppression. 
 
3.3. pRB in senescence 
Cellular senescence (or simply senescence) was described for the first time as a 
mechanism to explain the limited proliferation of normal cells in culture (Hayflick 1965). 
Further studies revealed the linking of telomere shortening to replicative senescence 
(Harley et al. 1990), a process that drives cells in an irreversible no proliferative state. 
In fact, senescent cells, although metabolically active, stop proliferation in an 
irreversible way. p27 and p16 are often overexpressed and cells usually become 
resistant to cell death stimuli. Nowadays, the molecular mechanisms involved in this 
biological process have not been totally characterized; however, the p53-p21 and p16-
pRB pathways seem to play a fundamental role in senescence induction and 
maintenance (Campisi and d'Adda di Fagagna 2007; Fiorentino et al. 2009). 
Different causes of senescence have been described, including telomere-
dependent senescence, DNA-damage-initiated senescence, senescence caused by 
chromatin perturbation, and oncogene-induced senescence (Campisi and d'Adda di 
Fagagna 2007). In addition, several findings reveal an important role of senescence as 
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a mechanism to limit the risk of neoplastic transformation, strongly suggesting a tumor 
suppressor property of cellular senescence (Campisi 2001). 
Focusing on the Retinoblastoma protein, pRB re-expression in some tumor cells 
was found to induce senescence and inhibit telomerase activity (Xu et al. 1997). Thus, 
pRB may play a causal role in senescence induction by eliciting p27 accumulation 
(Alexander and Hinds 2001). Moreover, the recruitment of heterochromatin proteins 
and pRB to E2F-responsive promoters causes their stable repression, coinciding with 
senescence-associated heterochromatic foci (SAHF) formation, underlying the 
importance of pRB in senescence induction and revealing new mechanisms of tumor 
suppression by pRB (Narita et al. 2003). 
To note, p107 and p130 were found to play distinct roles in the regulation of 
senescence: while p107 was required for initiation of accelerated senescence in the 
pRB-null DU45 human prostate cancer cell line, the knock down of p130 promoted 
premature senescence in these cells even in the absence of genotoxic stimuli 
(Lehmann et al. 2008). In contrast, other reports propose that p130 could be a master 
regulator for the sustained arrest of the cell cycle (Helmbold et al. 2006; Fiorentino et 
al. 2009). 
 
3.4. How cancer cells escape from pRB regulation of the cell cycle? 
The Retinoblastoma protein regulates G1-to-S progression of the cell cycle by 
inhibiting E2F activity and by recruiting chromatin-modifying enzymes that further 
repress transcription. As a scaffold, pRB promotes correct interactions between 
different proteins to best perform important biological functions: it is involved in embryo 
development and tissue differentiation, in DNA replication and it concurs in DNA 
damage response and regulation of apoptosis. 
Not surprisingly, cancer cells exploit pRB loss-of-function for oncogenic 
transformation. RB1 gene mutations are found in both hereditary and sporadic cancer 
types. In addition, oncoviral proteins block pRB interaction with E2F factors to promote 
uncontrolled cell proliferation. Alterations in proteins involved in pRB 
phosphoregulation promote defects in cell cycle progression’s control and, finally, 
interference with Retinoblastoma pathway could also support cancer cells’ evasion 
from apoptosis (Chau and Wang 2003). 
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4. pRB in programmed cell death regulation 
4.1. Cell death: overview 
Cell death is the biological process in which a cell, or a group of cells, quit all 
their biological functions. It is possible to distinguish a programmed cell death, which 
includes apoptosis and autophagy, and a non-physiological cell death or necrosis 
(Fuchs and Steller 2015). 
The word “autophagy” was coined by the discoverer of lysosomes, Christian de 
Duve (De Duve 1963) and refers to a cellular process that guarantee correct 
degradation and recycling of unnecessary cellular components. The formation of a 
double-membrane vesicle, the autophagosome, and its fusion with a lysosome, allows 
the correct execution of autophagy. In the context of programmed cell death, it is a 
current matter of debate if autophagy acts directly in dying cells or as a survival 
mechanism (Tsujimoto and Shimizu 2005). 
The first description of apoptosis dates to 1842, thanks to the work of Carl Vogt 
and later description of Walther Flemming in 1885. It was in 1972, with the works of 
Kerr, Wyllie and Currie (Kerr et al. 1972) and Brenner, Horvitz and Sulston (awarded in 
2002 with the Nobel prize in medicine), when the term apoptosis acquired new interest. 
Apoptosis is a highly controlled cellular process, with different morphologically 
identifiable stages, that allows the “suicide” of a single cell. During the firsts steps, cell 
loses contact with its tissue of origin. Irreversible condensation (pyknosis) and 
fragmentation of the chromatin (karyorrhexis) precede cell contraction, ruffling and 
blebbing of the plasmatic membrane and subsequent formation of apoptotic bodies. 
These are recognized by macrophages, which complete their degradation.  
From a molecular point of view, p53 is a major regulator of the “intrinsic pathway” 
of apoptosis. Once the apoptotic program is active, p53 induces the expression of pro-
apoptotic BH1-2-3 proteins (Bax, Bak) and BH3 only proteins (Bim, Bid, Puma, Noxa), 
and inhibits expression of the anti-apoptotic proteins Bcl2 and BclxL. The previously 
mentioned pro-apoptotic proteins displace Bcl2 and BclxL from mitochondrial 
membrane causing the Mitochondrial Membrane Permeabilization (MMP). The drop of 
mitochondria’s membrane potential and the following stretch of the mitochondria’s 
crests and disruption of its membrane, allow the release to the cytoplasm of apoptosis-
inducing factor (AIF), cytochrome c and apoptotic protease activating factor-1 (Apaf-1). 
Apoptosome, the result of the interaction between cytochrome C and Apaf-1, triggers 
caspase 9 activation, which in turn, active the executioner caspase 3. 
Caspase 3 is active also in the “extrinsic pathway” or “death ligand pathway”.  
One of these pathways is mediated by Fas/FasL. Fas ligand (FasL or CD95L) is a 
type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. 
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The binding to its receptor, FAS receptor (FasR)- also known as apoptosis antigen 1 
(APO-1 or APT)- cluster of differentiation 95 (CD95) or tumor necrosis factor receptor 
superfamily member 6 (TNFRSF6), promotes receptor’s tetramerization and 
subsequent recruitment of Fas-associated-death-domain (FADD). FADD, in turn, 
recruits and activate caspase 8 in the so-called DISC-complex (Death-inducing 
signaling complex), which activates caspase 3. 
The main differences between apoptosis and necrosis is that necrosis is caused 
by external factors of the cell or tissue, that characterize it as a non-physiological-
passive process. While apoptosis is a genetically regulated mechanism, in which 
chromatin is condensed and specifically cleaved in internucleosomal sites, necrosis is 
characterized by chromatin flocculation. Furthermore, in necrosis there is no formation 
of cellular bodies, and the complete lysis of groups of cells evoke an inflammatory 
state. 
The theory most widely accepted today is that the death program would be 
running all the time, if it was not because it is continually thwarted by the survival-
promoting or anti-death stimuli.  
 
4.2. pRB and apoptosis regulation: anti-apoptotic or pro-apoptotic functions? 
While the role of pRB in cell cycle regulation and cell growth inhibition has been 
extensively investigated and characterized, its role in apoptosis regulation has not 
been characterized in much detail. Indeed, its role in apoptosis regulation is still 
controversial (Indovina et al. 2015). 
Massive apoptosis detected in Rb1-/- mice during embryogenesis suggested, at 
first, an anti-apoptotic function of pRb (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 
1992; Chau and Wang 2003). Furthermore, pRb1-/- MEFs not only showed 
inappropriate S phase entry, but also predisposition to apoptosis (Almasan et al. 1995). 
According to an anti-apoptotic role, forced expression of pRB in pRB deficient cells 
inhibited ionizing radiation-induced apoptosis (Haas-Kogan et al. 1995). 
In contrast, a pro-apoptotic role of pRB has been found also. Indeed, forced 
expression of a phospho-resistant mutant version of pRB (RB-PSM) in C33A cells (a 
pRB deficient tumor cell line) increased cisplatin-induced cell death (Knudsen et al. 
1999). However, wt pRB and RB-PSM failed to inhibit C33A proliferation (Knudsen et 
al. 1999), therefore suggesting that cell cycle inhibition and apoptosis induction by 
hypo-phosphorylated pRB are mechanistically unrelated. Furthermore, under DNA 
damage condition, pRB was found associated with E2F1 in transcriptionally active pro-
apoptotic promoters (Ianari et al. 2009), suggesting again a pro-apoptotic role of pRB 
under genotoxic stress. Consistent also with a pro-apoptotic role of pRB, the formation 
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of a trimeric complex pRB-HDM2-p53 was reported in which pRB binding to HDM2 
inhibits its ubiquitinase activity and promotes p53 stabilization (Hsieh et al. 1999).  
The interaction between pRB and HDM2 was also described to support an anti-
apoptotic function of pRB. Janicke and colleagues identified a specific caspase-
dependent cleavage at the carboxyl terminus of pRB and suggested that the loss of the 
last 42 amino acids could be one of the first steps of the apoptosis program (Janicke et 
al. 1996). Since HDM2 interacts with the carboxyl terminus of pRB (Xiao et al. 1995), 
Janicke and colleagues proposed that the lack of HDM2 interaction with cleaved pRB 
might promote HDM2 degradation and therefore activate p53-dependent apoptosis 
(Janicke et al. 1996). Supporting this hypothesis, the use of a cleavage-resistant pRB 
mutant (RB MI) in Rb1-/- MEFs, attenuated death induced by TNF. However, no effects 
were observed in a leukemia cell line, Jurkat, treated with anti-CD95 (Tan et al. 1997). 
The description of a pro-apoptotic function of the c-Abl tyrosine kinase (Theis and 
Roemer 1998; Wang 2000) and pRB inhibitory effect on this kinase (Welch and Wang 
1993) are also consistent with an anti-apoptotic function of pRB. 
A second E2F-binding site was found at the carboxyl terminus of pRB that was 
specific for E2F1 (Dick and Dyson 2003), the only known member of the E2F family 
with pro-apoptotic capacity (Qin et al. 1994; Shan and Lee 1994; Wu and Levine 1994; 
DeGregori et al. 1997; Lazzerini Denchi and Helin 2005). While mutation of several 
residues in the small pocket of pRB (RB-ΔE2F-G) did not affect its capacity to repress 
E2F1 transactivation of pro-apoptotic gene promoters following DNA damage, it 
impaired its transcriptional repressive capacity on other E2F family members (Dick and 
Dyson 2003). It seems that acetylation of Lysine 873/874 of pRB, that occurs in 
response to DNA damage, regulates this specific interaction (Markham et al. 2006). 
Further characterization of this interaction identified pRB residues Methionine 851 and 
Valine 852 as necessary for the interaction: a pRB mutant in which both amino acids 
were substituted with an Alanine (RB ΔS) loss the capacity to inhibit the apoptosis 
induced by E2F1 overexpression, suggesting again an anti-apoptotic role of pRB 
(Julian et al. 2008). E2F1 binding at pRB carboxyl terminal specific site is maintained 
even in the hyper-phosphorylated (and presumably inactive) pRB form (Cecchini and 
Dick 2011). 
Thus, apoptotic regulation mediated by Retinoblastoma protein could be 
mediated by specific phosphorylation events. However contradictory information 
increases the complexity of this theme. 
In fact, there are additional conflicting data on the effect of pRB phosphorylation 
over its capacity to regulate apoptosis. 
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The capacity of pRB to regulate apoptosis might be controlled by specific 
phosphorylation of Serine 567. This residue is phosphorylated only under hyper-
proliferative conditions and it is a signal for pRB degradation and cell death, supporting 
the notion that pRB expression is required to inhibit both cell proliferation and death 
(Ma et al. 2003). Furthermore, hyper-phosphorylated pRB inhibits the pro-apoptotic 
function of nuclear phosphoprotein pp32 (ANP32A), suggesting the possibility that 
cancer cells could gain both proliferative and survival advantages in the presence of 
inactive, hyper-phosphorylated pRB (Adegbola and Pasternack 2005).  
In contrast, a pro-apoptotic function was proposed again upon the finding that 
pRB interacted with the pro-apoptotic protein Bax in the mitochondria. Induction of pRb 
expression in MEF increased apoptosis in cells treated with TNFα plus cycloheximide 
and this apoptosis was reduced in Bax-/- MEFs, suggesting that pRb induces apoptosis 
directly at the mitochondria though Bax interaction (Hilgendorf et al. 2013). This 
interaction appeared to be promoted by phosphorylation of pRB at Serine 807 
(Antonucci et al. 2014). Supporting also a pro-apoptotic role for pRB, the knock-down 
of Phosphatase Nuclear Targeting Subunit (PNUTS) increased apoptosis only in pRB-
expressing tumor cell lines, coinciding with E2F1 dissociation from pRB and the 
induction of caspase 8 activity (De Leon et al. 2008). 
Finally, although some experiments suggest that pRB silencing decreases 
apoptosis induced by genotoxic agents in T98G human glioblastoma cells and in U2OS 
human osteosarcoma cells (Ianari et al. 2009), the loss of Retinoblastoma in breast 
cancer patients increases sensitivity to antimetabolite treatment and it is the only 
predictive factor of good clinical outcome (Derenzini et al. 2008). 
It seems therefore that pRB can either promote apoptosis or inhibit apoptosis 
depending on cellular settings and environmental conditions (Bosco and Knudsen 
2005; Masselli and Wang 2006; Indovina et al. 2015). Very little is known however 
about the role of p107 or p130 in apoptosis. Indeed, to the best of our knowledge, there 
is no published information about the role of p107 in apoptosis and there is very little 
information about the role of p130 in this process. The presence of p130 in human 
retinoblastoma samples is associated with increase of apoptotic index (Bellan et al. 
2002) and p130 promotes radiation-induced cell death in the glioblastoma hamster cell 
line HJC12 (Pucci et al. 2002). However, the overexpression of p130 in CAOV-3 
ovarian cell line can inhibit apoptosis triggered by camptothecin and doxorubicin 
(Tonini et al. 2004), suggesting, as for pRB, a dual role of p130 in cell death regulation 
regarding the cellular context and the environmental condition. 
In conclusion, great efforts have been made to reveal Retinoblastoma functions 
in cell biology, but the molecular mechanisms involved in these functions are not 
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completely understood yet (Dyson 2016). A better knowledge of pRB role in apoptosis 
regulation and the use of new technologies to characterize better the heterogeneity of 
cancer biology could promote new therapeutic strategies aimed to the Retinoblastoma 
pathway (Knudsen and Wang 2010). 
In this study, we wanted to perform a comprehensive structure-function analysis 
to define the major domains of pRB involved in the regulation of E2F activity, cell cycle 
progression, proliferation and cell death. Our findings strongly suggest that cell death 
inhibition by pRB requires a prolonged cell cycle arrest that cannot be provided by 
p107 or p130. 
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The main objectives of this thesis are: 
 
1- To determine the role of the Retinoblastoma family members in cell death 
regulation. 
 
2- To assess the contribution of the different functional domains of pRB to cell 
death regulation. 
 
3- To investigate whether cell death regulation by pRB is related to its capacity to 
inhibit E2F activity, cell cycle progression, or DNA replication. 
 
4- To generate a 3-dimensional model of full-length pRB for structural analysis. 
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1. Plasmids 
pcDNA3-HA-RB wt, pcDNA3-HA-RB 1-792, and pcDNA3-RB 379-928 were 
created by subcloning HA-RB wt, HA-RB 1-792, and RB 379-928 cDNA fragments 
from pSG5L-HA-RB, pSG5L-HA-RB 1-792, and pSG5L-RB 379-928, respectively into 
pcDNA3. pSG5L-RB 379-928, pSG5L-empty, pSG5L-HA-RB wt, pSG5L-HA-RB Δ503, 
pSG5L-HA-RB Δ529, pSG5L-HA-RB Δ535, pSG5L-HA-RB Δ542, pSG5L-HA-RB 
Δ651, pSG5L-HA-RB Δ657, pSG5L-HA-RB Δ678, pSG5L-HA-RB Δ685, pSG5L-HA-
RB 661W, and pSG5L-HA-RB 567L were previously described (Sellers et al. 1998) and 
generously provided by W. Sellers (Dana-Farber Cancer Institute, Boston MA). To 
generate pcDNA3-p107-HA and pcDNA3-HA-p130, p107-HA and HA-130 were 
excised from pCMVp107-HA (Zhu et al. 1993) and pcDNA1-HA-p130 (Vairo et al. 
1995) and subcloned into pcDNA3. pCMVp107-HA and pcDNA1-HA-p130 were a gift 
from M. Ewen; Dana-Farber Cancer Institute.  
pcDNA3-HA-RB/p130 C-ter, pcDNA3-HA-p130/RB C-ter and pcDNA3-HA-RB C-
ter were generated in the laboratory. SacII restriction site in nucleotide position 50-55 
of RB wt (ID: 5925) was eliminated in pcDNA3-HA-RB wt by site-directed mutagenesis, 
introducing a silent mutation (primer sense 5’ – 
CCGCCGCCGCTGCCGCAGCGGAACCCCCGGCAC – 3’; primer antisense 5’ -
GTGCCGGGGGTTCCGCTGCGGCAGCGGCGGCGG – 3’). Subsequently, a SacII 
restriction site was introduced in nucleotide position 2356-2361 of RB wt by site-
directed mutagenesis, introducing two silent mutations (primer sense 5’ - 
CACCAATACCTCACATTCCGCGGAGCCCTTACAAGTTTCC – 3’; primer antisense 5’ 
– GGAAACTTGTAAGGGCTCCGCGGAATGTGAGGTATTGGTG – 3’). Digestion of 
pcDNA3-HA-RB wt with BamHI and SacII excised a cDNA fragment of RB from 
nucleotide 1 to nucleotide 2359 and maintained in the plasmid the carboxyl terminal 
nucleotide sequence (nucleotides 2360-2787). Site-directed mutagenesis was used 
also to introduce a SacII restriction site in nucleotide position 3049-3054 of p130 (ID: 
5934) in pcDNA3-HA-p130 (primer sense 5’ – 
CATCTACATCAAACAGCCGCGGACATTTGCCATGAAG – 3’; primer antisense 5’ – 
CTTCATGGCAAATGTCCGCGGCTGTTTGATGTAGATG – 3’). This mutagenesis 
introduced I1017P and K1018R mutations (P and R are the same amino acids present 
in wt pRB). This plasmid was digested with BamHI and SacII to excise a p130 cDNA 
fragment from nucleotide 1 to nucleotide 3052 and to maintain the carboxyl terminal 
sequence of p130 in the plasmid (nucleotides 3053-3420). To generate pcDNA3-HA-
RB/p130, nucleotides 1-2359 from RB were ligated to plasmid pcDNA3-HA-p130 
previously mutated and digested with BamHI and SacII. pcDNA3-HA-p130/RB was 
generated by ligation of p130 nucleotides 1-3052 to plasmid pcDNA3-HA-RB 
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previously mutated and digested with BamHI and SacII. pcDNA3-HA-RB C-ter was 
generated by ligating a BamHI-AgeI-SacII adapter to pcDNA3-HA-RB previously 
mutated and digested with BamHI and SacII. pcDNA3-HA-RB ΔS was generated by 
site-directed mutagenesis of plasmid pcDNA3-HA-RB wt using oligonucleotides 5’ - 
GAGAAGTTCCAGAAAATAAATCAGGCGGCA TGTAACAGCGACCGTGTG – 3’ and 
5’ – CACACGGTCGCTGTTACATGCCGCCTGATTTATTTTCTGGAACTTCTC – 3’. 
The mutation consists in two amino acids substitution: M851A and V852A. pcDNA3-
HA-RB ΔI (harboring a Stop-codon in nucleotide 2659 of RB) was generated by PCR 
using pcDNA3-HA-RB wt as template plasmid and the following oligonucleotides 5’ – 
ACTGTTGGATCCATGCCGCCCAAAACCCCCCGAAAAACGG – 3’ and 5’ – 
TGACAACTCGAG TCA ATCTGCTTCATCTGATCCTTC – 3’. pcDNA3-HA-RB 13S 
was generated by site-directed mutagenesis of plasmid pcDNA3-HA-RB wt using 
oligonucleotides 5’-
GCAGTATGCTTCCACCAATATGGATGCACCACCATTGTCACCAATACCTC – 3’, 5’- 
GAGGTATTGGTGACAATGGTGGTGCATCCATATTGGTGGAAGCATACTGC – 3’, 5’- 
AAAAATGACTCCAAGCTCAACAATCTTAGTATCAGAGCCATGGGAAATTGGTGAAT
CATTC – 3’, and 5’ – 
GAATGATTCACCAATTTCCCATGGCTCTGATACTAAGATTGTTGAGCTTGGAGTCA
TTTTT – 3'.  
pcDNA3-HA-p27 was generated by subcloning p27 cDNA from pcDNA3-p27 
(kindly provided by C. Calés; Instituto de Investigaciones Biomédicas Alberto Sols, 
CSIC-UAM, Madrid, Spain) into pcDNA3-HA. pcDNA3-HA-p21 was generated by 
subcloning from pRcCMVp21 (Adams et al. 1996), a generous gift from W.G. Kaelin 
(Dana-Farber Cancer Institute). pcDNA3-HA-BRG1 was generated from pSV-BRG1, 
(kindly provided from B. Belandia; Instituto de Investigaciones Biomédicas Alberto 
Sols), and pcDNA3-HA-BRG1 DN (K785R; Khavari et al. 1993) was generated by site-
directed mutagenesis of plasmid pcDNA3-HA-BRG1, using the following 
oligonucleotides: 5’ – GAGATGGGCCTGGGGCGAACCATCCAGACCATCG – 3’ and 
5’ – CGATGGTCTGGATGGTTCGCCCCAGGCCCATCTC – 3’. 
pcDNA3-9E10, pcDNA3-9E10-RB wt and pcDNA3-9E10-RB NPC were 
generously provided by S. Mittnacht (Cancer Institute, University College London, 
United Kingdom). 
pcDNA3-HA-NLS-Stop was generated introducing the SV40 Large T antigen 
nuclear localization signal as previously described (Kalderon et al. 1984). The RB 1-
792 cDNA fragment from excised from pcDNA3-HA-RB 1-792 and subcloned into this 
plasmid to obtain pcDNA3-HA-NLS-RB 1-792. 
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pCMV-BamNeo-flag-RB wt and pCMV-BamNeo-flag RB C-ter were generated in 
the laboratory from plasmid pcDNA3-flag-RB wt and pcDNA3-flag-RB C-ter, 
respectively (in turn generated in the laboratory). pCMV-BamNeo-flag-RB SE was 
kindly provided by J. Wang (Center for Molecular Genetics, and Cancer Center, 
University of California, San Diego, California, USA). 
pBB14 plasmid was provided from L. W. Enquist (Department of Molecular 
Biology, Princeton University, NJ). This plasmid expresses a variant of the Green 
Fluorescent Protein (US9-GFP) able to anchorage to cellular membranes. 
BG-Luc 3xE2F-DHFR wt, BG-Luc 3xE2F-DHFR mut, pGL2- E2F1 promoter wt, 
pGL2-prom E2F promoter mutated, pGL2-CDC6 promoter used in luciferase assays 
were previously described (Campanero et al. 2000). pGL2-p73 promoter that was 
generated by subcloning from pGL3-p73 promoter (a generous gift from M.C. Marín 
Vieira; Universidad de León, Leon, Spain). pRL-null (Promega; E-2271) was used for 
transfection normalization. 
 
2. Cell culture and transfection 
Saos2 cells were obtained from ATCC and grown at 37°C in a 5% CO2 
humidified incubator, in Dulbecco’s modified Eagle media (DMEM; Gibco, Thermo 
Fisher Scientific), supplemented with 10% fetal bovine serum (FBS; Gibco- Thermo 
Fisher Scientific), 100 mM Glutamine (Gibco- Thermo Fisher Scientific), 100 U/ml 
Penicillin (Penilevel; Laboratorios ERN, S.A.) and 100 µg/ml Streptomycin sulfate 
(Laboratorio Reig Jofré, S.A.). 
Transfection was performed with the Calcium Phosphate method, as previously 
described (Campanero et al. 2000). Co-transfection with a GFP-encoding plasmid 
(pBB14) was performed to select transfected cells by flow cytometry. 
For experiments of cell cycle synchronization, cells were treated with 0.4 mM L-
Mimosine (M-0253; Sigma-Aldrich), 1mM Hydroxyurea (H-8627; Sigma-Aldrich), 25 
ng/ml Nocodazole (M-1404; Sigma-Aldrich) or 10 µg/ml Cycloheximide (C-1988; 
Sigma-Aldrich). 
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3. Immunoblot analysis and antibodies 
To prepare protein extracts, cells were centrifuged 5 minutes at 500xg; cell 
pellets were suspended in 4 pellet volumes of WCE buffer (20 mM Hepes pH 7.9, 1 
mM EDTA, 400 mM NaCl, 25% Glycerol; supplemented with 0.5% NP40, 1 mM 
Na3VO4, 1 mM PMSF, 1 mM NaF, 1 µg/ml Pepstatin A, 1 µg/ml Leupeptin, 1 µg/ml 
Bestatin, and 2 µg/ml Aprotinin) and left 30 minutes on ice (vortexing occasionally). 
After 15 minutes of centrifugation at maximum speed at 4 °C, supernatants were 
collected and stored at -80°C. 
Cytoplasmic/nuclear fractionation was performed using the NP-40 method. Cells 
were centrifuged 5 minutes at 500xg; cell pellets were suspended in 4 pellet volumes 
of Buffer A (10 mM Hepes pH 7.9, 10 mM KCl, 0,1 mM EDTA, 0,1 mM EGTA; 1 mM 
Na3VO4, 1 mM PMSF, 1 mM NaF, 1 µg/ml Pepstatin A, 1 µg/ml Leupeptin, 1 µg/ml 
Bestatin and 2 µg/ml Aprotinin) and left 15 minutes on ice. NP-40 was added (0.6%) 
and the samples were vortexed and centrifuged 20 seconds at 14,000xg. The 
supernatant was transferred into a new tube and centrifuged at maximum speed for 15 
minutes at 4°C. The new supernatant was transferred into a new tube and used as 
cytosolic fraction after adding Glycerol to reach a final concentration of 20%. The pellet 
obtained after the brief centrifugation was washed twice in Buffer A and suspended in 
2.7 pellet volumes of Buffer B (20 mM Hepes pH 7.9, 20 % Glycerol, 1,5 mM MgCl2 0.2 
mM EDTA; 1 mM Na3VO4, 1 mM PMSF, 1 mM NaF, 1 µg/ml Pepstatin A, 1 µg/ml 
Leupeptin, 1 µg/ml Bestatin and 2 µg/ml Aprotinin) before adding 0.3 pellet volumes of 
4.2 M NaCl. Samples were maintained 20 minutes on ice, vortexing occasionally. The 
supernatant obtained from a final centrifugation at 14,000xg for 10 minutes at 4°C was 
used as the nuclear extract. 
Protein concentration was measured using the Lowry method (DC Protein Assay 
Reagent kit, Bio-Rad 500-0116). Proteins (50 µg) were fractionated by SDS 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) and transferred to a nitrocellulose 
membranes (AmershamTM ProtranTM 0,45 µm NC; GE Health Care Life Science). The 
following primary antibodies were used: anti-HA.11 (Covance); anti-RB (c-ter) (sc50X; 
Santa Cruz Biotechnology); anti-RB (pocket) (554136; BD Pharmigen); anti-αTubulin 
(T-9026, Sigma-Aldrich); anti-TFIIH (sc293X; Santa Cruz Biotechnology). Primary 
antibodies were detected with goat anti-mouse IgG antibody (IRDye 800CW_926-
32210; LI-COR), donkey anti-rabbit IgG antibody (IRDye800CW_926-32213; LI-COR), 
or goat anti-mouse IgG antibody (IRDye 680_926-32220), employing LI-COR Odyssey 
technology. Immunoblot bands quantification was performed with Image Studio Lite 
Ver 5.2 (LI-COR). 
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4. Immunofluorescence 
Cells were seeded in 10-mm-diameter cover glasses; fixed with 4% 
Formaldehyde (Riedel-de Haën, 15512), 4% Saccharose (Riedel-de Haën, 16104) in 
1xPBS for 15 minutes at RT; and permeabilized using 0.1% Triton®X-100 (T-8787; 
Sigma-Aldrich) in 1xPBS for 5 minutes at RT. Blocking was performed for 30 minutes 
at RT in blocking solution (5% BSA and 5% goat serum in 1xPBS). Anti HA-11 
(Covance) or anti-RB (c-ter) (sc50X; Santa Cruz Biotechnology) were used as primary 
antibodies and detected, respectively, with goat anti-mouse Alexa Fluor® 546 
conjugate (A-11030; Molecular probers- Thermo Fischer Scientific) or goat anti-rabbit 
Alexa Fluor® 546 conjugate (A-11035; Molecular probers- Thermo Fischer Scientific). 
Nuclei were stained with DAPI (D-1306; Molecular probes- Thermo Fischer Scientific). 
Images were obtained with a SP5 Leica confocal microscope equipped with a 
63x magnification lens. 
 
5. Cell cycle analysis, cell proliferation assay and cell growth assay 
For cell cycle analysis, cells were fixed in ice cold 70% ethanol and stained with a 
solution of 69 mM Propidium Iodide (S-4170; Sigma-Aldrich) in 38 mM sodium citrate. 
10 µg/ml RNase (R-6513; Sigma-Aldrich) was added and samples were incubated 30 
minutes at 37°C. DNA profiles were analyzed by flow-cytometry using FACS-Can or 
FACS-Canto II (Becton Dickinson) and Cell Quest or FACS-Diva software (Becton 
Dickinson), respectively. Flowing Software 2.5.1 (Turku Centre for Biotechnology, 
University of Turku, Finland) was employed for cell cycle analysis and representation of 
cell cycle histograms, while ModFit LT software (Verity software house) was employed 
for cell cycle’s phases quantification. At least 10.000 events (or 10.000 GFP-positive 
events in the case of transfected cells) were evaluated. 
Proliferation was determined by flow cytometry analysis of EdU incorporation. 
Cells were incubated with 10 µM EdU in complete DMEM medium for 2 hours at 37°C 
in a 5% CO2 humidified incubator. Cells were stained following manufacturer's 
instructions (Click-iT® EdU Alexa Fluor® 647 Flow Cytometry Assay Kit; Molecular 
Probes- Thermo Fischer Scientific). Due to incompatibility of Click-iT kit with GFP 
fluorescence, a GFP-Tag Polyclonal Antibody was used (A-6455; Molecular Probes- 
Thermo Fisher Scientific) and detected with Alexa Fluor® 488-conjugated goat anti-
mouse IgG secondary antibody (A-11029; Molecular Probes- Thermo Fischer 
Scientific). Samples acquisition was performed with FACS-Canto II (Becton Dickinson) 
and FACS-Diva software (Becton Dickinson) was used for the analysis. At least 10.000 
GFP-positive events were evaluated. 
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Cell growth was assessed by counting viable cells (unstained by trypan blue) 
using a hemocytometer. Cells (100.000) were seeded in six-well plates treated 24 
hours later with various drugs and subjected to ionizing radiation (IR;15 Gy) 24h later. 
The effects of ionizing radiation on cell growth were determined after 72 hours. 
 
6. Luciferase assay 
Luciferase assays were performed using Dual-Luciferase® Reporter Assay 
System (E-1910; Promega) following manufacturer’s instructions. Cells were collected 
and lysed with 100 µl of Passive Lysis Buffer 1X (PLB 1X) and 50 µl were employed for 
the analysis. Analysis was performed with GloMax® 96 Microplate Luminometer 
(Promega), using 25 µl of LARII buffer, to stimulate Luciferase emission, and 25 µl of 
Stop and Glo buffer, to inactivate Luciferase and allow Renilla emission. 
 
7. Nuclei fragmentation assay 
Cells were plated on 22-mm2 cover glasses and subjected 24h later to IR (15 Gy) 
using the biological irradiator SHEPHERD MARK I. Cells were fixed in ice cold 70% 
ethanol 72 later, washed with 1xPBS, and stained with a 69 mM Propidium Iodide (S-
4170; Sigma-Aldrich) solution in 38 mM sodium citrate, diluted four times in 1xPBS. 
Transfected cells were exposed to IR (15 Gy) 48 hours after transfection. Images were 
acquired with an Axiophot Zeiss microscope and a 20X magnification lens, using DP-
manager and DP-controller software. For each experiment, 200 cells or 200 GFP+ cells 
(transfected cells) were counted. 
 
8. Bioinformatic study and analysis 
Bioinformatic studies and analysis were performed at the Bioinformatic unit of the 
Spanish National Centre for Cardiovascular Research (CNIC). I-Tasser software suite 
v5.0 (Yang et al. 2015) was employed for modeling with homology, whereas Disopred 
v3.16 program (Jones and Cozzetto 2015) was used to predict secondary structure, 
disordered regions and protein binding profiles.  
The loopmodel tool (Mandell et al. 2009; Stein and Kortemme 2013) of Rosetta 
suite v3.5 release 2015.38.58158 (www.rosettacommons.org) was used to close the 
gap between the N and A domains of pRB-prerefine and B and C domains of pRB_B-
Ctail in the final model of the protein. For refinement, the relax tool (Nivon et al. 2013; 
Conway et al. 2014) of Rosetta suite v3.5 release 2015.38.58158 
(www.rosettacommons.org) was used. 
The representation of the pRB model was created with PyMOL 1.8.x. 
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9. Figures’ elaboration and statistical analysis 
Figures were elaborated with Adobe Photoshop CS6 and Adobe Illustrator CS6. 
Graphs and ANOVA test were generated with GraphPad Prism 6 (GraphPad Software, 
Inc.) considering significant results with a p-value <0.05. 
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1. Effects of RB family members in cell cycle arrest and cell death inhibition 
To compare the activities of the pocket proteins, pRB, p107 and p130, we 
forced their expression in the osteosarcoma cell line Saos2 because this cell line is 
considered as a good model for the study of pRB function in the context of cell 
cycle and apoptosis regulation. The Saos2 cell line was derived from a primary 
osteosarcoma of an 11 years-old Caucasian girl in 1973 (Fogh et al. 1977). This 
cell line is p53 deficient and expresses a truncated, non-functional form of pRB, 
but, responds to forced expression of wild-type (Thomas et al. 2004) pRB, as 
observed by changes in morphology and inhibition of growth rate, colony formation 
in soft agar, and tumorigenicity in nude mice (Huang et al. 1988; Shew et al. 1990). 
In 1995 Haas-Kogan et al. showed that ionizing radiation (IR) induced apoptosis in 
a time- and dose-dependent manner in Saos2 cells and that forced expression of 
wt pRB decreased IR-induced apoptosis in these cells (Haas-Kogan et al. 1995).  
To confirm the sensitivity of Saos2 cells to IR, we exposed them to a 15Gy 
dose and analyzed their cell cycle distribution after several periods of time. We 
found an accumulation of cells in G2/M 16-24h post-IR (probably because these 
cells are also p53-negative), followed by an increase of a sub-G0 population, 
indicative of cell death, particularly 72h after IR (Fig. 1A).  
To determine the role of pRB in cell death regulation, we transfected a pRB-
encoding pcDNA3 vector or the empty vector together with a green fluorescent 
protein (GFP)-encoding plasmid in Saos2 cells and exposed them to 15 Gy of IR. 
Cell cycle analysis 72h after the treatment showed that RB-expressing cells (GFP+) 
accumulated in G0/G1 and showed an almost negligible sub-G0 population (Fig. 
1B, bottom-right panel), whereas the non-transfected cells (GFP-) showed an 
almost negligible G0/G1 population and substantial G2/M and sub-G0 populations 
(Fig. 1B, bottom-left panel) that were comparable to those observed in cells 
transfected with an empty pcDNA3 plasmid (Fig. 1B, top panels). These results 
suggested that, as previously described (Haas-Kogan et al. 1995), pRB inhibits IR-
induced cell death. We confirmed these results analyzing nuclei fragmentation in 
irradiated cells. Indeed, the overexpression of wt pRB in IR-treated cells sharply 
decreased the presence of fragmented nuclei in GFP+ cells relative to control 
transfected GFP+ cells (Fig. 1C, 1D). 
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Figure 1. The Retinoblastoma protein inhibits IR-induced apoptosis in Saos2 cells.        
(A) Saos2 cells were co-transfected with pCDNA3 and a GFP-encoding plasmid (pBB14) 
to analyze the cell cycle in transfected cells. Cells were irradiated (15 Gy) 48 hours after 
transfection and their cell cycle distribution was analyzed by flow cytometry 2 hours, 4 
hours, 8 hours, 16 hours, 24 hours, 48 hours and 72 hours later. (B) Saos2 cells were co-
transfected with pBB14 plus either pRB-encoding or empty pcDNA3 to analyze the cell 
cycle in transfected (GFP+) cells and in non-transfected cells (GFP-). Cells were irradiated 
(15 Gy) 48 hours after transfection and their cell cycle distribution was analyzed by flow 
cytometry 72 hours later. (C) Representative images of nuclei fragmentation and (D) 
percentage of GFP+ cells with fragmented nuclei in cells treated as in (B) (n=3; media ± 
SEM). ****p<0.0001 vs empty; by one-way ANOVA with Tukey's multiple comparisons test. 
 
Next step was to compare the activity of the pocket proteins (Fig. 2A) in cell 
proliferation, cell cycle control, E2F activity regulation, and cell death. The 
expression of HA-tagged pRB, p107, and p130 in transiently transfected Saos2 
cells was confirmed by immunoblotting (Fig. 2B). As expected, forced expression 
of pRB inhibited cell proliferation (Fig. 2C) and induced accumulation of cells in the 
G0/G1 phase of the cell cycle relative to control cells (Fig. 2D). The 
overexpression of either p107 or p130 strongly inhibited cell proliferation and 
accumulated cells in G0/G1, but less markedly than pRB expression (Fig. 2C, 2D). 
Using a reporter plasmid with three copies of the wt E2F-binding site in the 
dihydrofolate reductase (DHFR) promoter, we found that the three pocket proteins 
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inhibited E2F activity similarly (Fig. 2E, filled bars). As expected, none of these 
proteins affected significantly the activity of a reporter driven by a mutant version of 
the E2F sites unable to bind E2F (Fig. 2E, empty bars). 
 
 
Figure 2. pRB is the only pocket family member that inhibits IR-induced cell death.        
(A) Schematic representation of pRB, p107 and p130. (B-D) Saos2 cells were co-
transfected with pBB14 plus vectors encoding the indicated HA-tagged pocket proteins. (B) 
Representative anti-HA and Tubulin (Tub) immunoblots (n=3). (C) Quantification of cell 
proliferation as assessed by flow cytometry evaluation of EdU incorporation, and (D) cell 
cycle analysis, represented as absolute increase in G1 cells relative to control-transfected 
cells, 48 hours after transfection (n=3; mean + SEM). (E) The indicated E2F-DHFR 
luciferase reporter plasmids were co-transfected with pRL-null in asynchronously growing 
Saos2 cells in the presence of plasmids encoding the indicated pocket proteins or empty 
vector. 48 hours later, cell extracts were prepared and firefly and renilla luciferase assays 
were performed. Firefly luciferase values were normalized for renilla activity. Luciferase 
activity is shown relative to that in the presence of the empty vector (mean ± SEM; n=3). 
(F) Representative images of nuclear fragmentation and (G) percentage of GFP+ cells with 
fragmented nuclei 72h after IR exposure (15 Gy). Data are shown relative to empty vector 
as mean ± SEM (n=3). ****p<0.0001 vs empty; #p<0.05, ###p<0.001, ####p<0.0001 vs 
pRB; by one-way ANOVA with Bonferroni's multiple comparisons test (C, E) or with Tukey's 
multiple comparisons test (D, H). 
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We also assessed the capacity of the three pocket proteins to regulate cell 
death. While pRB forced expression sharply decreased IR-induced apoptosis in 
Saos2 cells, the overexpression of either p107 or p130 did not significantly inhibit 
or induce cell death (Fig. 2F, 2G). Together, these data indicate that while the 
pocket proteins share the capacity to inhibit E2F activity, cell cycle progression, 
and cell proliferation, pRB is the only pocket family member that possesses the 
capacity to inhibit cell death in a situation of DNA damage.  
 
2. The ability of pRB in cell death inhibition is not regulated by 
phosphorylation 
The control of cell cycle progression by pRB is strictly regulated by its 
phosphorylation state (Macdonald and Dick 2012; Rubin 2013). However, the 
phospho-regulation of pRB in cell death control is highly controversial (Dou et al. 
1995; Adegbola and Pasternack 2005; De Leon et al. 2008; Lentine et al. 2012; 
Antonucci et al. 2014). For this reason, we investigated the effect of the 
overexpression of a phospho-defective mutant of pRB (RB-NPC) in which all the 
putative CDK phosphorylation sites (Fig. 3A) were substituted by Alanine (Chew et 
al. 1998). Immunoblot analysis showed that pRB-wt and pRB-NPC levels were 
similar in transiently transfected Saos2 (Fig. 3B).  
 
 
Figure 3. Phospho-resistant pRB inhibits IR-induced cell death. (A) Schematic 
representation of RB NPC showing positions mutated to Ala. Saos2 cells were co-
transfected with pBB14 plus vectors encoding the indicated proteins or empty vector. (B) 
Representative anti-pRB (c-ter) immunoblot of these cells; the arrow and the arrowhead 
indicate the overexpressed proteins and a non-specific (ns) protein, respectively. Tubulin 
(Tub) was used as loading control. (C) Cell cycle analysis, represented as absolute 
increase in G1 cells relative to control-transfected cells, 48 hours after transfection (n=3; 
mean ± SEM). (D) Cells were exposed to IR (15 Gy) 48h after transfection and the 
percentage of GFP+ cells with fragmented nuclei 72h after IR exposure was determined; 
data are shown relative to empty vector as mean ± SEM (n=3). (C, D) **p<0.01, 
***p<0.001, ****p<0.0001 vs empty; #p<0.05 vs pRB; by one-way ANOVA with Tukey's 
multiple comparisons test. 
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Forced expression of either pRB-wt or pRB-NPC accumulated cells in G0/G1 
relative to control cells, but the phospho-defective mutant showed a significantly 
stronger effect (p<0.05) in G1 phase arrest than pRB-wt (Fig. 3C). However, both 
proteins inhibited IR-induced cell death with similar efficiency (Fig. 3D). Our data 
therefore indicate that phospho-deficient pRB, not only fails to promote apoptosis, 
but also inhibits cell death as efficiently as pRB-wt. 
 
3. The inhibition of cell cycle progression and cell death by pRB is not 
mediated by BRG1 
Brahma-related gene 1 or BRG1, is a member of the SWI/SNF family of 
proteins. Members of this family have helicase and ATPase activities that allow 
alterations in chromatin structure around genes that are directly regulated by these 
proteins. Following its isolation in 1993 (Khavari et al. 1993), BRG1 was found in 
complex with pRB (Dunaief et al. 1994; Strober et al. 1996) and it was described 
that BRG1 is required for pRB-mediated cell cycle arrest (Strobeck et al. 2000). 
We therefore hypothesized that BRG1 may be required for cell cycle arrest and 
inhibition of IR-induced cell death by pRB. If our hypothesis was correct, a 
dominant-negative version of BRG1 should inhibit the capacity of pRB to arrest 
cells in G1 and to inhibit IR-induced cell death.  
To challenge this hypothesis, we transiently transfected Saos2 cells with a 
plasmid encoding a previously described (Khavari et al. 1993) dominant-negative 
version of BRG1 (BRG1 DN) or wt BRG1 together with pBB14 and a plasmid 
encoding wt pRB. Expression of these proteins was confirmed by immunoblot 
analysis (Fig. 4A). The expression of wt BRG1 or that of BRG1 DN did not 
substantially modify the DNA profile of the cells or the percentage of cell survival 
following IR exposure in the absence of ectopic pRB, and also failed to suppress 
the inhibition of cell cycle progression or IR-induced cell death by pRB (Fig. 4B, 
4C). These data therefore strongly suggest that BRG1 does not mediate these 
inhibitory activities of pRB. 
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Figure 4 Effects of BRG1 and BRG1 DN over 
expression in Saos2 cell line.                       
Saos2 cells were transfected with pBB14 and 
plasmids encoding the indicated proteins.             
(A) Representative anti-HA immunoblot showing 
the expression of pRB (arrowhead) and that of 
either wt BRG1 or BRG1 DN (arrow) 48 hours after 
transfection (n=3). Tubulin (Tub) was used as 
loading control. (B) Cell cycle analysis, represented 
as absolute increase in G1 cells relative to empty 
vector, evaluated 48 hours after transfection (mean 
± SEM; n=3). (C) Percentage of GFP+ cells with 
fragmented nuclei 72h after exposure to IR (15 
Gy). Data are shown relative to empty vector 
(media ± SEM; n=3). ***p<0.001, ****p<0.0001 vs 
empty; by one-way ANOVA with Tukey's multiple 
comparisons test. 
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4. Study of the effects of the different pRB functional domains in cell cycle 
arrest and cell death inhibition 
Although the three pocket proteins share structural properties, the specific 
capacity of pRB to inhibit cell death could be potentially attributed to structural 
features unique to pRB. Indeed, p107 and p130 are more closely related to each 
other by sequence similarity than to pRB (Classon and Dyson 2001). The small 
pocket is the region with the highest homology between the three proteins and 
alterations of its sequence affect its activity in transcriptional regulation, 
differentiation induction and tumor growth suppression (Sellers et al. 1998). In 
contrast, the carboxyl terminus of pRB is the least homologous domain to p107 
and p130 (Hasan et al. 2013).  
 
4.1. The carboxyl terminal domain of pRB is necessary but not sufficient 
to inhibit cell death 
To understand the role of the various domains of pRB in cell cycle arrest and 
cell death inhibition, we used pRB mutant derivatives lacking one or more 
functional domains. The effect of the wild-type protein (RB wt) was compared with 
that of mutants lacking either the carboxyl terminal (RB 1-792) or the amino 
terminal domain (RB 379-928) or with that of two fragments of the carboxyl 
terminus of the protein, RB SE (768-928) (Welch and Wang 1995b) and RB C-ter 
(786-928) (Fig 5A).  
After transient transfection of Saos2 cells with plasmids encoding these 
proteins, we used western blotting to confirm their expression (Fig. 5B, 5C). We 
observed that RB 1-792 loss the capacity to inhibit cell proliferation (Fig. 5D), to 
arrest the cell cycle in G1 (Fig. 5E), to inhibit E2F activity (Fig. 5F) and to 
substantially protect cells from IR-induced death (Fig. 5G). Conversely, pRB large 
pocket (RB 379-928) inhibited all these processes as efficiently as the wild-type 
protein (RB wt) (Fig. 5D, 5G). Of note, the carboxyl terminal fragments of pRB (RB 
SE or RB C-ter) inhibited E2F activity as sharply as wt pRB (Fig. 5J) and 
substantially inhibited cell proliferation and cell cycle progression, but not as 
markedly as RB wt (Fig. 5H, 5I). However, RB SE and RB C-ter failed to inhibit IR-
induced cell death (Fig. 5K).  
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Figure 5. Functional 
analysis of pRB 
domains. (A) 
Schematic 
representation of pRB 
and indicated mutant 
derivatives RB 1-792, 
RB 379-928, RB SE 
and RB C-ter. Saos2 
cells were co-
transfected with 
pBB14 plus empty 
vector or (D-G) 
pcDNA3 encoding HA-
tagged versions of the 
indicated proteins or 
(H-K) pCMV encoding 
the indicated proteins. 
(B, C) Representative 
anti-HA, anti-pRB (c-
ter) or anti-pRB 
(pocket) immunoblots 
of these cells (n=3); 
the arrowhead 
indicates the position 
of RB 379-928. 
Tubulin (Tub) was 
used as loading 
control. (D, H) 
Quantification of cell 
proliferation as 
assessed by flow 
cytometry evaluation 
of EdU incorporation, 
and (E, I) cell cycle 
analysis, represented 
as absolute increase 
in G1 cells relative to 
control-transfected 
cells, 48 hours after 
transfection (n=3; 
mean ± SEM). (F, J) 
The wt E2F-DHFR 
luciferase reporter 
plasmid was co-
transfected with pRL-
null in asynchronously 
growing Saos-2 cells 
in the presence of 
plasmids encoding the 
indicated proteins or 
empty vector. 48 hours later, cell extracts were prepared and firefly and renilla luciferase 
assays were performed. Firefly luciferase values were normalized for renilla activity. 
Luciferase activity is shown relative to that in the presence of the empty vector (mean ± 
SEM; n=3). (G, K) Cells were exposed to IR (15 Gy) 48h after transfection and the 
percentage of GFP+ cells with fragmented nuclei 72h after IR exposure was determined. 
Data are shown relative to empty vector as mean ± SEM (n=3). *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 vs empty; #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001 vs 
pRB; by one-way ANOVA with Bonferroni's multiple comparisons test (D, F, H, J) or with 
Tukey's multiple comparisons test (E, G, I, K). 
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To complete our analysis of the pRB carboxyl terminal fragments RB SE and 
RB C-ter, we studied their subcellular localization. Cytoplasmic/nuclear 
fractionation showed a preferentially nuclear localization of the wild-type protein 
(RB wt), whereas similar levels of both RB SE and RB C-ter were detected in 
cytosolic and nuclear fractions (Fig. 6A, 6B). Confocal microscopy analysis of RB 
staining provided similar results (Fig. 6C). 
 
 
Figure 6. Sub-cellular localization of carboxyl terminal fragments of pRB.                        
(A) Representative anti-pRB (pocket) or anti-pRB (c-ter) immunoblots of cytoplasmic and 
nuclear fractions of Saos2 cells transfected with pBB14 plus empty vector or pCMV 
encoding the indicated proteins. Tubulin (Tub) was used as loading control of cytoplasmic 
extracts. (B) Quantification of the cytoplasmic/nuclear ratio of densitometric values from 
these immunoblots shown as mean ± SEM (n=3). (C) Representative confocal microscopy 
images (n=3) of Saos2 cells transfected as in (A) and stained with anti-RB (c-ter) and 
DAPI. GFP auto-fluorescence is also shown. Scale bar, 25µm. 
 
All these data allowed us to conclude that the amino terminus of pRB is not 
required for the regulation of cell cycle progression and cell death inhibition and 
that the carboxyl terminus is sufficient to block E2F activity and to inhibit cell cycle 
progression. Finally, the carboxyl terminus of pRB is necessary, but not sufficient, 
to inhibit IR-induced cell death.  
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4.2. Forced RB 1-792 expression in the nucleus does not recover its 
capacity to inhibit cell cycle progression or cell death 
A bipartite nuclear localization signal (NLS), important for its biological 
activities, has been found in the carboxyl terminus of Retinoblastoma protein 
between amino acids 860-876 (Zacksenhaus et al. 1993). The pRB mutant 
derivative RB 1-792, which loss the capacity to arrest the cell cycle and to inhibit 
cell death, consequently lacks this NLS. We therefore investigated whether the 
lack of activity of this mutant could be attributed to its sequestration in the cytosol. 
Once confirmed the expression of RB wt and RB 1-792 in transiently transfected 
Saos2 cells (Fig. 7A), we determined their levels in cytosolic and nuclear fractions 
of these cells. While RB wt was detected preferentially in the nuclear fraction, RB 
1-792 was preferentially detected in the cytosolic fraction (Fig. 7B, 7C). To force a 
nuclear localization of RB 1-792 we cloned the NLS of SV40 large tumor antigen 
(Kalderon et al. 1984) in the amino terminus of this mutant. The expression levels 
of this novel mutant, NLS-RB 1-792, were similar to those of RB 1-792 (Fig. 7A) 
but it was preferentially located in the nuclear fraction (Fig. 7B, 7C). Similar results 
were obtained by confocal microscopy analysis of RB staining in the same cells; 
RB wt and NLS-RB 1-792 were located mostly in the nucleus, whereas RB 1-792 
was found both in the cytosol and in the nucleus (Fig. 7D). Although NLS-RB 1-
792 showed a subcellular distribution similar to that of RB wt, it was as inactive as 
RB 1-792 arresting the cell cycle in G1 (Fig. 7E) or inhibiting IR-induced cell death 
(Fig. 7F).  
These data therefore indicate that the pRB carboxyl terminus plays a critical 
role in cell growth and cell death inhibition regardless its contribution to the 
preferential location of pRB in the nucleus. 
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Figure 7. The restoration of RB 1-792 nuclear location does not recover its capacity 
to inhibit cell cycle progression or cell death. Representative anti-HA immunoblots of 
Saos2 cells transfected with plasmids encoding the indicated proteins employing (A) 
whole-cell extracts or (B) cytosolic and nuclear fractions of the same cells (n=3). Tubulin 
(Tub) was used as loading control of whole-cell extracts and cytosolic fractions, whereas 
TFIIH was used as loading control of nuclear extracts. (C) Quantification of the 
cytoplasmic/nuclear ratio of densitometric values from these immunoblots after 
normalization with the corresponding loading control (n=3; mean ± SEM). (D) Saos2 cells 
were co-transfected with pBB14 and vectors encoding the indicated proteins. 
Representative confocal microscopy images (n=3) of anti-HA immunofluorescence, GFP 
autofluorescence and DAPI staining are shown. Scale bar, 25µm. (E) Quantification of cell 
cycle analysis in the same cells, represented as absolute increase in G1 cells relative to 
control-transfected cells (empty), 48 hours after transfection (n=3; mean ± SEM). (F) Cells 
transfected as in (E) were exposed to IR (15 Gy) 48h later and the percentage of GFP+ 
cells with fragmented nuclei was determined after 72h. Data are shown relative to empty 
vector as mean ± SEM (n=3). ****p<0.0001 vs empty; ####p<0.0001 vs pRB; by one-way 
ANOVA with Tukey's multiple comparisons test. 
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4.3. The carboxyl terminus of pRB does not confer cell death inhibition 
activity to p130 
We have shown that pRB is the only pocket family member with capacity to 
inhibit cell death and that its carboxyl terminus is required for this activity. Since 
the carboxyl terminus of pRB is the least homologous domain to p107 and p130, 
we constructed chimeric pRB/p130 and p130/pRB proteins exchanging only their 
carboxyl terminal fragments (Fig. 8A), and compared their functional activity with 
the non-chimeric wt pRB and p130 and with RB 1-792.  
 
Figure 8. Characterization of chimeric pRB/p130 proteins.                                          
(A) Schematic representation of pRB, p130, RB 1-792 and chimeric pRB/p130 and 
p130/pRB proteins. (B) Representative anti-HA immunoblot of Saos2 cells transfected with 
pBB14 plus pcDNA3 encoding the indicated HA-tagged proteins or empty vector (n=3). 
Tubulin (Tub) was used as loading control. (C) The wt E2F-DHFR luciferase reporter 
plasmid was co-transfected with pRL-null in Saos-2 cells in the presence of plasmids 
encoding the indicated proteins or empty vector. 48 hours later, cell extracts were prepared 
and firefly and renilla luciferase assays were performed. Firefly luciferase values were 
normalized for renilla activity. Luciferase activity is shown relative to that in the presence of 
the empty vector (mean ± SEM; n=3). (D-F) Saos2 cells were transfected as in (B) and cell 
proliferation (D) and cell cycle distribution (E) were determined by flow cytometry 
evaluation of percentage of EdU incorporation (mean ± SEM; n=3) and propidium iodide 
staining, respectively, in GFP+ cells 48 hours after transfection. Data in (D) represent the 
absolute increase in G1 cells relative to empty vector (mean ± SEM; n=3). (F) Cells were 
exposed to IR (15 Gy) 48h after transfection and the percentage of GFP+ cells with 
fragmented nuclei was determined 72h after IR exposure.  Data are shown relative to 
empty vector as mean ± SEM (n=3). **p<0.01, ***p<0.001, ****p<0.0001 vs empty; 
##p<0.01, ###p<0.001, ####p<0.0001 vs pRB; by one-way ANOVA with Bonferroni's 
multiple comparisons test (C, D) or with Tukey's multiple comparisons test (E, F). 
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Western blotting of Saos2 cells transiently transfected with the different HA-
tagged pocket proteins expression plasmids showed that all proteins were 
expressed at detectable levels (Fig. 8B). Although pRB/p130 levels were lower 
than those of wt proteins, this chimera inhibited E2F transactivation activity as 
efficiently as the wt proteins or as the p130/pRB chimera (Fig. 8C) and arrested 
cells in G1 as modestly as wt p130 (Fig. 8D), suggesting that the chimeric proteins 
were not completely misfolded. However, both chimeras failed to significantly 
inhibit cell proliferation and IR-induced cell death (Fig. 8E, 8F). Together, these 
results suggest that pRB cell growth and cell death inhibitory activities are 
mediated by a very precise configuration of the small pocket and the carboxyl 
terminus.  
 
4.4. The association of the carboxyl terminus of pRB with E2F1, c-Abl or 
HDM2 is not required for inhibition of IR-induced cell death 
In addition to a general binding site for E2F factors in pRB, involving the 
large pocket, an E2F1-specific binding site was found in the carboxyl terminus of 
pRB (Dick and Dyson 2003). While wt pRB blocked the proapoptotic activity of 
E2F1, RB ΔS (M851A; V852A) a mutant derivative of this binding site, failed to 
inhibit E2F1-induced apoptosis (Julian et al. 2008). c-Abl, a proapoptotic protein 
tyrosine kinase positively regulated by ATM in response to DNA damage, is 
negatively regulated by pRB (Wang 2000). A mutant pRB protein unable to bind c-
Abl, RB 13S, was constructed (Whitaker et al. 1998). Caspases cleave the c-
terminal 42 amino acid peptide of pRB during apoptosis induction and RB ΔI, a 
mutant RB protein that mimics the caspase-cleaved product, bound E2F1 but not 
MDM2 (Janicke et al. 1996). 
To investigate whether the association of pRB with E2F1, c-Abl or HDM2 
(the human ortholog of MDM2) mediates its capacity to inhibit cell death, we 
compared the functional activity of wt pRB with that of RB ΔS, RB 13S, and RB ΔI. 
We used site-directed mutagenesis to create HA-tagged versions of the three 
mutant derivatives (Fig. 9A) and forced their expression in Saos2 cells. Their 
expression levels were similar to those of wt pRB and they arrested cells in G1 and 
inhibited IR-induced cell death as efficiently as wt pRB (Fig 9B-9J). 
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Figure 9. Cell cycle and cell death regulation by RB ΔS, RB ΔI and RB 13S.                     
(A) Schematic representation of RB wt, RB ΔS, RB ΔI and RB 13S, indicating the 
mutations introduced in these proteins. (B-J) Saos2 cells were transfected with pBB14 plus 
vectors encoding the indicated HA-tagged proteins. (B, E, H) Representative anti-HA 
immunoblots of these cells (n=3). Tubulin (Tub) was used as loading control. (C, F, I) Cell 
cycle analysis, represented as absolute increase in G1 cells relative to empty vector, 
evaluated 48 hours after transfection in GFP+ cells (n=3; mean ± SEM). (D, G and J) Cells 
were exposed to IR (15 Gy) 48h after transfection and the percentage of GFP+ cells with 
fragmented nuclei was determined 72h after IR exposure. Data are shown relative to empty 
vector as mean + SEM (n=3 for RB ΔS and RB ΔI; n=2 for RB 13S). **p<0.01, ***p<0.001, 
****p<0.0001 vs empty; by one-way ANOVA with Tukey's multiple comparisons test. 
 
In addition, RB ΔS and RB 13S inhibited DNA replication and E2F 
transactivation capacity as efficiently as wt pRB (Fig. 10). Together, these data 
strongly suggest that the association of pRB c-terminal with E2F1, c-Abl, or HDM2 
does not mediate cell death inhibition and cell growth inhibition capacities of pRB. 
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Figure 10. Regulation of DNA replication and E2F transactivation activity by RB ΔS 
and RB 13S. (A) Saos2 cells were transfected with pBB14 plus vectors encoding the 
indicated HA-tagged proteins and cell proliferation was assessed by flow cytometry 
evaluation of the percentage of EdU incorporation in GFP+ cells 48 hours after transfection 
(mean ± SEM; n=3). (B) The wt E2F-DHFR luciferase reporter plasmid was co-transfected 
with pRL-null in Saos2 cells in the presence of plasmids encoding the indicated proteins or 
empty vector. 48 hours later, cell extracts were prepared and firefly and renilla luciferase 
assays were performed. Firefly luciferase values were normalized for renilla activity. 
Luciferase activity is shown relative to that in the presence of the empty vector (mean ± 
SEM; n=3). ***p<0.001, ****p<0.0001 vs empty; by one-way ANOVA, Bonferroni's multiple 
comparisons test. 
 
4.5. The small pocket is critical for pRB inhibition of cell death 
The small pocket does not inhibit cell growth (Qin et al. 1992) but is required 
for cell growth suppression (Sellers et al. 1998). Accordingly, we hypothesized that 
although RB 1-792 failed to inhibit IR-induced cell death, it could be critical for cell 
death inhibition. To study the contribution of the small pocket to cell death 
inhibition, we used a set of mutants in which residues in the pRB sequence that 
are highly conserved in p107 and p130 were replaced with the flexible linker’s 
sequence NAAIRS (Wilson et al. 1985; Sellers et al. 1998) (Fig.11A). Mutants 
were named according to the first substituted amino acid; for example, residues 
503-508 were replaced with NAAIRS in RB Δ503.  
We transiently transfected Saos2 cells with plasmids encoding HA-tagged 
versions of pRB mutants and analyzed their expression by Western blotting of 
whole cell extracts. All mutants were produced at comparable levels (Fig.11B). 
Analysis of the capacity of these mutants to inhibit cell proliferation (Fig.11C), 
arrest cells in G1 (Fig.11D) and inhibit E2F transactivation activity (Fig.11E) 
identified three groups of mutants according to their efficiency relative to wt pRB; 
RB Δ503, RB Δ529 and RB Δ685 acted like the wt pRB; RB Δ657 and RB Δ678 
loss these activities; and RB Δ535, RB Δ542 and RB Δ651 showed an 
intermediate effect (Fig. 11C, 11E). We then analyzed the capacity of selected 
mutants representative of each group (RB Δ685, RB Δ657 and RB Δ651) to inhibit 
IR-induced cell death and found that RB Δ685 inhibited cell death as efficiently as 
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wt pRB, whereas RB Δ657 failed to prevent nuclei fragmentation and RB Δ651 
showed an intermediate activity (Fig.11F, 11G). 
 
 
 
Figure 11. Functional characterization of 
pRB small pocket mutants.                   
(A) Schematic representation of the 
localization of the different mutants in pRB. 
(B-D) Saos2 cells were co-transfected with 
pBB14 and plasmids encoding the 
indicated HA-tagged proteins. (B) 
Representative anti-HA and Tubulin (Tub) 
immunoblots of these cells (n=3). (C) 
Quantification of cell proliferation by flow 
cytometry evaluation of the percentage of 
GFP+ cells incorporating EdU 48h after 
transfection (mean ± SEM; n=3), and (D) 
cell cycle analysis of GFP+ cells, 
represented as absolute increase in G1 
cells relative to empty vector, evaluated 48 
hours after transfection (mean ± SEM; 
n=3). (E) The wt E2F-DHFR luciferase 
reporter plasmid was co-transfected with 
pRL-null in Saos2 cells in the presence of 
plasmids encoding the indicated proteins or 
empty vector and firefly and renilla 
luciferase assays were performed 48h later. 
Firefly luciferase values were normalized 
for renilla activity. Luciferase activity is 
shown relative to that in the presence of the 
empty vector (mean ± SEM; n=3). (F-G) 
Saos2 cells were co-transfected with 
pBB14 and plasmids encoding the 
indicated HA-tagged proteins. (F) 
Representative anti-HA and Tubulin (Tub) 
immunoblots of these cells (n=3). (G) Cells 
were exposed to IR (15 Gy) 48h after 
transfection and the percentage of GFP+ 
cells with fragmented nuclei was 
determined 72h after IR exposure. Data are 
shown relative to empty vector as mean ± 
SEM (n=3). *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 vs empty; #<0.05, ##p<0.01, 
###p<0.001, ####p<0.0001 vs pRB; by 
one-way ANOVA with Bonferroni's multiple 
comparisons test (C and E) or with Tukey's 
multiple comparisons test (D and G). 
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These data therefore indicate that not only the c-terminal of pRB is required 
for cell death inhibition but also its small pocket. To further confirm the relevance of 
the small pocket in cell death inhibition, we assessed the capacity of pRB mutants 
in the A and B domain identified in human tumors: the low-penetrance mutant RB 
R661W (Onadim et al. 1992; Lohmann et al. 1994) and the non-functional RB 
S567L (Yandell et al. 1989) (Fig. 12A). We transiently transfected plasmids 
encoding these mutants in Saos2 cells and observed that both mutants were 
expressed (Fig. 12B). Like RB Δ651, the low-penetrance mutant RB R661W 
inhibited cell cycle progression and IR-induced cell death, but less efficiently than 
RB wt (Fig. 12C, 12D). In contrast, RB S567L failed to inhibit cell cycle progression 
and cell death (Fig. 12C, 12D). 
 
 
 
Figure 12- Functional characterization of RB 661W and RB 567L mutants.                        
(A) Schematic representation of the localization of RB 661W and RB 567L mutants in pRB.    
(B-D) Saos2 cells were co-transfected with pBB14 and plasmids encoding the indicated 
HA-tagged proteins. (B) Representative anti-HA and Tubulin (Tub) immunoblots of these 
cells (n=3). (C) Cell cycle analysis of GFP+ cells, represented as absolute increase in G1 
cells relative to empty vector, evaluated 48 hours after transfection (mean ± SEM; n=3). (D) 
Cells were exposed to IR (15 Gy) 48h after transfection and the percentage of GFP+ cells 
with fragmented nuclei was determined 72h after IR exposure. Data are shown relative to 
empty vector as mean ± SEM (n=3). **p<0.01, ***p<0.001, ****p<0.0001 vs empty; #p<0.05 
vs pRB; by one-way ANOVA with Tukey's multiple comparisons test. 
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5. Correlation between long-term cell cycle arrest in G0/G1 and cell death 
inhibition 
How pRB inhibits cell death? Why the over expression of p107, p130 or the 
Carboxyl terminus of pRB induces an increase in G1, but fail to inhibit IR-induced 
cell death? Are cell growth and cell death regulation independently regulated or is 
there a correlation between cell cycle arrest and cell death inhibition?  
 
5.1. Permanent G0/G1 arrest induced by drugs avoid nuclei fragmentation 
Our data show a tight correlation between the inhibitory activities of pRB in 
cell proliferation and cell death. We therefore hypothesized that pRB-independent 
means of cell cycle inhibition might also inhibit IR-induced cell death. To challenge 
this hypothesis, we used a pharmacological approach to either arrest or 
synchronize pRB-deficient Saos2 cells in different phases of the cell cycle and 
assess their sensitivity to IR. 
Low concentration of the protein synthesis inhibitor cycloheximide (CHX) 
arrests cells in G1 (Hung et al. 1996; Liu et al. 2010). We therefore assess its 
capacity to stably arrest cells in G1 and to inhibit IR-induced cell death. Although 
the DNA profile of cells treated 24h with CHX did not show a marked G1 arrest, its 
capacity to block cell cycle progression in G1 was evident when cells previously 
synchronized with Nocodazole were released for 24h in the presence of CHX (Fig. 
13A). Contrary to previous observations showing that CHX did not induce cell 
death in Saos2 cells (Morimoto et al. 1999), we found that CHX modestly induced 
death of these cells, as evidenced by the presence of a sub-G1 population in CHX-
treated cells (Fig. 13A) and by the decrease in the number of cells after 3 days of 
CHX treatment (Fig. 13B). Despite its modest toxicity, cells arrested by CHX 
treatment were resistant to IR-induced cell death (Fig. 13C).  
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Figure 13. Cell cycle arrest by cycloheximide blocks IR-induced cell death.                
Saos2 cells were treated with 10 µg/ml cycloheximide (CHX) or in the absence of stimuli 
(NT) and subjected to ionizing radiation (15 Gy). Alternatively, Saos2 cells were treated 
24h with 25 ng/ml nocodazole (Noc); treated with nocodazole, washed and cultured without 
additional stimuli for 6h (Noc+6h) or 24h (Noc+24h); or washed and treated for additional 
24h with 10 µg/ml CHX (Noc+CHX). (A) Representative DNA profiles of these cells. (B) 
Cells were irradiated 24h after CHX addition and the effect on cell growth of indicated 
treatments was evaluated 3 days later by counting viable cells in the presence of trypan 
blue. Data show cell numbers at the end of the experiment relative to numbers immediately 
before exposure to IR (media ± SEM; n=3). (C) Percentage of cells with fragmented nuclei 
72 hours after irradiation (IR) or in non-irradiated cells (NO IR) (media ± SEM; n=3). 
 
Our data show a correlation of stable cell cycle arrest and resistance to IR-induced 
cell death, but we cannot rule out that CHX inhibits apoptosis by blocking the 
expression of pro-apoptotic proteins. We therefore assessed the capacity of 
additional drugs that block cell cycle progression without inhibiting protein 
synthesis. In particular, we used mimosine (Mim), a tyrosine-related alkaloid that 
arrests cells in the late G1 phase of the cell cycle by inhibiting DNA replication 
initiation; hydroxyurea (HU), an antineoplastic drug that inhibits DNA synthesis and 
induces cell death in S phase and arrests surviving cells in this phase; and 
nocodazole (Noc), an antineoplastic agent that inhibits microtubules polymerization 
and arrests cells in G2/M before killing them. 
As expected, cells treated for 24h with Mim, HU, or Noc were arrested in late 
G1, S, or G2/M respectively, whereas cells treated sequentially with Noc and Mim 
or with Mim and HU were arrested late in G1 or at the G1/S transition, respectively 
(Fig. 14A). Similarly, cells cultured 6h in the absence of drugs after 24h of 
treatment with Mim, HU, or Noc were synchronized early in S, late in S, or early in 
G1, respectively (Fig. 14A).  
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Long-term treatment (4 days) of cells with Mim or HU not only blocked cell 
proliferation but also induced cell death in a major fraction of the cells and 
therefore decreased the total number of cells in culture (Fig. 14B, empty bars). Of 
note, irradiation of surviving cells, stably arrested in G1 (Mim) or early in S (HU), 
did not decrease the number of cells any further (Fig. 14B, filled bars), suggesting 
that stably arrested cells may be resistant to IR-induced cell death.  
 
 
 
Figure 14. Saos2 cells stably arrested with mimosine or hydroxyurea are resistant to 
IR-induced cell death. Saos2 cells were either arrested or synchronized in different cell 
cycle phases using various drugs combinations and exposed to IR (15 Gy). Cells treated 
with 0.4 mM L-mimosine (Mim), 1mM hydroxyurea (HU), or 25 ng/ml nocodazole (Noc) for 
4 days to stably arrest them late in G1, in S, or in G2/M, respectively, were irradiated 30h 
after the beginning of the treatment. Alternatively, cells were treated with 0.4 mM L-
mimosine, 1mM hydroxyurea, or 25 ng/ml nocodazole for 24h, washed to eliminate the 
stimuli, and exposed to IR 6h later to irradiate cells synchronized early in S (Mim+6h), late 
in S (HU+6h) or early in G1 (Noc+6h), respectively. Finally, cells were treated with 0.4 mM 
L-mimosine or 25 ng/ml nocodazole for 24h, washed to eliminate these stimuli, and 
exposed to IR after an additional treatment with 1mM hydroxyurea (Mim+HU) or 0.4 mM L-
mimosine (Noc+Mim) for another 24h to irradiate cells stably arrested late in G1 or at the 
G1-S transition, respectively. (A) Representative DNA profiles of these cells immediately 
before IR treatment (n=3). (B) The effect on cell growth of the indicated treatments was 
evaluated 3 days after irradiation by counting viable cells in the presence of trypan blue. 
Data show cell numbers at the end of the experiment relative to numbers immediately 
before exposure to IR (media ± SEM; n=3). (C) Percentage of cells with fragmented nuclei 
3 days after irradiation (media ± SEM; n=3). NS, non-synchronized cells; NO IR, non-
irradiated cells; IR, irradiated cells; †, no cells survived. 
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Accordingly, cells stably arrested late in G1 (Mim and Noc+Mim), early in S 
(HU), or at the G1/S transition (Mim+HU) were extremely resistant to IR-induced 
cell death, as determined by the near absence of fragmented nuclei in these cells 
(Fig. 14C). In contrast, irradiation of cells synchronized, but not stably arrested, 
early in G1 (Noc+6h), early in S (Mim+6h), or late in S (HU+6h) sharply decreased 
the number of cells in culture relative to non-irradiated cells (Fig. 14B) and 
markedly induced nuclei fragmentation (Fig. 14C), indicating that non-stably 
arrested cells were sensitive to IR.  
We also determined the sensitivity of cells treated for 24h with Mim and then 
released for different periods to time and found that regardless the cell cycle phase 
in the G1-S transition, most non-stably arrested cells showed fragmented nuclei 
upon irradiation (Fig. 15). Finally, cells synchronized in G2/M (treated 24h with Noc 
and then washed) were also sensitive to IR-induced cell death (Fig. 14C). We 
could not assess the sensitivity of cells stably arrested in G2/M because no cells 
survived a 4-day treatment with nocodazole (Fig. 14C).  
 
  
Figure 15. IR induces death of cells 
synchronized in late G1-early S but 
not of cells stably arrested in late 
G1. Saos2 cells were treated with 0.4 
mM L-mimosine for 4 days (Mim) or 
for 24 hours and then washed and 
incubated in the absence of stimuli for 
the indicated times before irradiation 
(15 Gy). (A) Representative DNA 
profiles of these cells immediately before irradiation. (B) Percentage of cells with 
fragmented nuclei 72 hours after irradiation exposure (IR) and in the non-irradiated 
population (NO IR) (media ± SEM; n=3). NS, non-synchronized cells. 
 
Together, our data strongly support the idea that a permanent arrest in the 
G1 phase of the cell cycle is necessary and sufficient to inhibit IR-induced cell 
death.  
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5.2. pRB is the only pocket protein that arrest cells in G0/G1 in the long-
term 
Since a pharmacological long-term arrest in the G1 phase of the cell cycle 
inhibits IR-induced cell death, we investigated whether pRB family members and 
pRB carboxyl terminus have the capacity to induce a long-term cell cycle arrest. 
We therefore analyzed the short-term and long-term (48h and 5 days after 
transfection, respectively) functional consequences of forcing the expression of 
pRB family members and mutant derivatives of pRB. We included in this analysis 
the three members of the Retinoblastoma family and the two pRB carboxyl 
terminal domain proteins, (RB SE and RB C-ter). We selected 5 days after 
transfection as a long-term time point because we have assessed cell death in IR-
treated cells 5 days after transfection. 
Plasmids encoding HA-tagged Retinoblastoma family members were 
transiently transfected in Saos2 cells and the expression of these proteins was 
detected both 48h and 5 days (Fig.16A). Although all the pocket proteins induced 
increase in G1 phase of the cell cycle at short time, only pRB retained the capacity 
to arrest cells after 5 days (Fig.16B). Forced expression of RB SE or RB C-ter was 
also detected in the short- and in the long-term (Fig. 16C) and, like p107 and p130, 
both proteins inhibited the cell cycle 48h after transfection, but failed to arrest cells 
in G1 in the long-term (Fig. 16D).  
To confirm that pRB is the only pocket protein capable of stably arrest the 
cell cycle in G1, we used an alternative experimental approach taking advantage 
of the capacity of nocodazole to block the cell cycle in G2/M unless cells are 
previously arrested in G1 (Whitaker et al. 1998). We transiently transfected Saos2 
cells with plasmids encoding each pocket protein and treated them two days later 
with Nocodazole for another 24h. The expression of these proteins was 
determined at the end of the experiment and we found that it was not affected by 
the treatment (Fig. 16E). As expected, nocodazole induced accumulation of 
control-transfected cells in G2/M (Fig. 16F). While forced expression of pRB 
blocked nocodazole-induced accumulation of cells in G2/M, the overexpression of 
p107 or p130 poorly inhibited the arrest in G2/M induced by nocodazole (Fig. 16F). 
Similarly, the ectopic expression of RB SE or RB C-ter was not affected by 
nocodazole (Fig. 16G) and failed to block nocodazole-induced arrest in G2/M (Fig. 
16H).  
Together, these data indicate that the accumulation of cells in G0/G1 
induced by p107, p130, RB SE, or RB C-ter in the short-term is not the 
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consequence of a permanent arrest of the cell cycle and further support the notion 
that long-term cell cycle arrest in G0/G1 inhibits IR-induced cell death. 
 
 
 
Figure 16. pRB is the only pocket protein with long-term capacity to arrest cells in 
G1. Saos2 cells were co-transfected with pBB14 and plasmids encoding the indicated 
proteins. (A-D) Two days and 5 days after transfection, protein extracts were prepared and 
the cell cycle was analyzed. (A, C) Representative anti-HA and anti-RB immunoblots (n=3) 
of these cells, Tubulin (Tub) was used as loading control. (B, D) Cell cycle analysis, 
represented as absolute increase in G1 cells relative to empty vector, evaluated 48 hours 
(filled bars) and 5 days (empty bars) after transfection (mean ± SEM; n=3). (E-H) Two days 
after transfection, Saos2 cells were treated with 25 ng/ml nocodazole (or DMSO) for 24 
hours. (E, G) Representative anti-HA and anti-RB immunoblots (n=3) of these cells. (F, H) 
Cell cycle analysis, represented as increase in G2/M cells relative to DMSO-treated cells 
(mean ± SEM; n=3). **p<0.01, ***p<0.001, ****p<0.0001 vs empty; by two-way ANOVA 
with Tukey's multiple comparisons test (B, D) or one-way ANOVA with Bonferroni's multiple 
comparisons test (F, H). 
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5.2.1. pRB is the only pocket protein that inhibits E2F activity in the 
long-term 
The capacity of the pocket proteins to inhibit cell cycle progression has been 
linked to their capacity to inhibit E2F activity (Dyson 1998). As pRB is the only 
pocket protein that inhibits cell cycle progression in the long-term, we investigated 
the long-term capacity of pRB family members, RB 1-792, and RB C-ter to inhibit 
E2F activity using luciferase reporter vectors driven by various E2F-responsive 
promoters. We transiently co-transfected Saos2 cells with plasmids encoding 
these proteins and reporter vectors driven by the promoters of E2F1, CDC6, tumor 
protein p73 (TP73), or the E2F1 promoter with an inactive E2F site (E2F1 mut 
promoter).  
We found that the wt E2F1 promoter was sharply inhibited by all pocket 
proteins and by RB C-ter 48h after transfection and that pRB was the only of these 
proteins that inhibited the activity of this promoter in the long-term as efficiently as 
in the short-term (Fig. 17A). The overexpression of p107 modestly inhibited its 
activity, whereas forced expression of p130, RB 1-792, or RB C-ter did not 
substantially affect the activity of this promoter 5 days after transfection (Fig. 17A). 
None of these proteins affected the activity of the E2F1 mut promoter (Fig. 17B). 
Similarly, pRB was the only of these proteins that inhibited the activity of the TP73 
or the CDC6 promoter in the long-term as efficiently as in the short-term (Fig. 17C, 
17D). Overexpressed p107 and p130 inhibited the activity of these promoters in 
the short-term as markedly as pRB, but negligibly affected their activity 5 days 
after transfection (Fig. 17C, 17D).  
We conclude that pRB is the only pocket protein able to permanently inhibit 
E2F activity, and propose that this feature is linked to its unique capacity to arrest 
the cell cycle in the long-term and to inhibit cell death.  
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Figure 17. Short-term and long-term regulation of E2F activity by pRB family 
members and mutant derivatives. Luciferase dual-reporter assay of Saos2 cells co-
transfected with plasmids encoding the indicated proteins, a renilla expression plasmid and 
the Firefly luciferase reporter plasmids driven by (A) the wt E2F1 promoter, (B); an E2F1 
promoter with mutant E2F-binding sites; (C) the wt TP73 promoter; and (D) the wt CDC6 
promoter. Values of luciferase emission were analyzed 48 hours and 5 days after 
transfection and normalized with renilla and with the media of each experiment. Data are 
shown as mean ± SEM (n=3). *p<0.05, **p<0.01, **p<0.001, ****p<0.0001 vs empty; by 
two-way ANOVA with Bonferroni's multiple comparisons test. 
 
5.3. The CIP/KIP inhibitors p21 and p27 inhibit cell cycle progression only 
transiently and do not prevent IR-induced cell death 
Inhibition of Cyclin/CDK complexes by the CIP/KIP family members p21, 
p27, and p57 can block cell cycle progression independently of pRB (Vidal and 
Koff 2000). We therefore investigated whether these proteins arrest the cell cycle 
in the long-term and inhibit IR-induced cell death. Saos2 cells were transiently 
transfected with plasmids encoding HA-tagged versions of p21, p27, pRB or RB 1-
792 and their expression was confirmed by immunoblotting 48h and 5 days later 
(Fig.18A). While pRB, p21, and p27 sharply inhibited cell proliferation and arrested 
cells in G1 48h after transfection, pRB was the only of these proteins that 
maintained its inhibitory activity 5 days after transfection (Fig. 18B, 18C). 
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Accordingly, pRB was the only of these proteins that markedly inhibited IR-induced 
cell death (Fig. 18D). 
 
Figure 18 Cell growth and cell death 
regulation by p27 and p21. Saos2 cells 
were co-transfected with pBB14 and 
plasmids encoding the indicated 
proteins. (A) Representative anti-HA 
immunoblots (n=3) comparing protein 
expression 48 hours and 5 days after 
transfection. Tubulin (Tub) was used as 
loading control. (B) Quantification of cell 
proliferation by flow cytometry evaluation 
of the percentage of GFP+ cells 
incorporating EdU 48h and 5 days after 
transfection (mean ± SEM; n=3); and (C) 
cell cycle analysis of GFP+ cells, 
represented as absolute increase in G1 
cells relative to empty vector, evaluated 
48 hours (filled bars) and 5 days (empty 
bars) after transfection (mean ± SEM; 
n=3). (D) Cells were exposed to IR (15 
Gy) 48h after transfection and the 
percentage of GFP+ cells with 
fragmented nuclei was determined 72h 
after IR exposure. Data are shown 
relative to empty vector as mean ± SEM (n=3). *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 vs empty; by (B) two-way ANOVA with Bonferroni's multiple comparisons test 
or (C)Tukey's multiple comparisons test, and by (D) one-way ANOVA with Tukey's multiple 
comparisons test.  
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6. The pRB small pocket and carboxyl terminus are structurally integrated 
6.1. Biochemical evidence of the structural integration of the small pocket 
and carboxyl terminus of pRB. 
Since the small pocket and the carboxyl terminal domain of pRB are both 
required for cell death inhibition, we considered several possible models to explain 
their involvement: 1) the presence of both domains is required for the correct 
formation of a binding site for a protein partner X required for cell death inhibition 
(Fig. 19A, top left); 2) stable binding to partner X requires simultaneous interaction  
with small pocket and carboxyl terminal domains (Fig.19A, top right); 3) the 
simultaneous and independent interaction of pRB with two partners, X and Y, 
through the small pocket and the carboxyl terminus, respectively, is required for 
cell death inhibition (Fig. 19A, bottom left); and 4) the interaction between pRB 
partners X and Y is required for cell death inhibition and pRB, interacting with them 
through its small pocket and its carboxyl terminus, acts as an scaffold to facilitate 
their interaction (Fig.19A, bottom right). 
If the small pocket and the carboxyl terminus were required for the 
interaction with partner X (model 2) or to bring together partners X and Y (model 
4), the simultaneous expression of wt pRB with either RB 1-792 or RB carboxyl 
terminal proteins would compete for the interaction with partner X (model 2) or 
partners X and Y (model 4) and would therefore inhibit cell death. To challenge 
these two models, we transiently co-transfected Saos2 cells with RB wt and an 
excess of RB 1-792, RB SE or RB C-ter and confirmed their expression in the cells 
by immunoblotting (Fig. 19B). We found that forced expression of RB 1-792 or the 
carboxyl terminal pRB fragments did not block the capacity of wt pRB to inhibit cell 
cycle progression (Fig.19C) or IR-induced cell death (Fig. 19D), therefore 
suggesting that models 2 and 4 are not valid. Although pRB carboxyl terminal 
fragments modestly inhibited IR-induced cell death in the absence of wt pRB in this 
particular set of experiments, they showed no substantial effect in previous 
experiments (compare with data in Fig. 5). 
If model 3 was correct, the expression of the small pocket and the carboxyl 
terminus of pRB as independent fragments should enable their interaction with 
partners X and Y and inhibit cell death. To test this hypothesis, we co-transfected 
Saos2 cells with RB 1-792 plus RB SE or RB C-ter and confirmed their expression 
(Fig.19E). Co-expression of pRB carboxyl terminal fragments (RB SE or RB C-ter) 
with RB 1-792 accumulated cells in G1 (Fig.19F) as efficiently as in the absence of 
RB 1-792 (compare with Fig. 19C), but failed to substantially inhibit IR-cell death 
(Fig. 19G). Together, these data strongly suggest that models 2, 3, and 4 are not 
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valid and therefore support the notion that the small pocket and the carboxyl 
terminus are structurally integrated to create a specific domain required for cell 
death inhibition. 
 
 
 
Figure 19. Biochemical evidence of the structural integration of the small pocket and 
carboxyl terminus of pRB. (A) Models depicting the interaction of pRB with potential 
protein partners required for cell death inhibition. (B-G) Saos2 cells were co-transfected 
with pBB14 and plasmids encoding the indicated proteins. (B, E) Representative anti-HA 
and anti-RB (c-ter) immunoblots (n=3) of these cells. Tubulin (Tub) was used as loading 
control. (C, F) Cell cycle analysis, represented as absolute increase in G1 cells relative to 
empty vector, evaluated 48 hours after transfection (mean ± SEM; n=3). (D, G) Cells were 
exposed to IR (15 Gy) 48h after transfection and the percentage of GFP+ cells with 
fragmented nuclei was determined 72h after IR exposure.  Data are shown relative to 
empty vector as mean ± SEM (n=3). *p<0,05, **p<0.01, ***p<0.001, ****p<0.0001 vs 
empty; by one-way ANOVA with Tukey's multiple comparisons test. 
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6.2. In-silico model of human Retinoblastoma protein 
To gain insight into the structural relationship between the small pocket and 
the carboxyl terminus of pRB in the absence of a crystallographic structure of the 
whole protein, we have performed an in-silico three-dimensional (3D) model of the 
protein based on the available crystallographic structure of small domains of pRB.  
To obtain the in-silico 3D model of human pRB, we submitted its Fasta 
sequence (Uniprot ID: P06400, residues 2-928) to a local implementation of I-
Tasser software suite v4.4 (Yang et al. 2015) for threading modeling with 
homology and selected the best model, with minimal energy and best structural 
alignment to the published (Burke et al. 2012) crystal structure of the pocket 
domain deposited in the Protein Data Bank under the accession code pdb ID: 
4eljA, RB-prerefine (Fig. 20A). In this model, the terminal end of the carboxyl 
domain has a short tail that does not fold with the protein core and projects to the 
exterior. This uncommon folding suggested that it is a disordered region and, to 
confirm this hypothesis, we analyzed this sequence with Disopred v3.16 program, 
a software that predicts secondary structures, disordered regions and protein 
binding profiles of proteins (Jones and Cozzetto 2015). This analysis identified four 
disordered regions corresponding to the four domains of the protein: amino 
terminus (N-term), A and B domains, and the carboxyl terminus (Fig. 20B). In the 
RB-prerefine model, the folding of A and B domains is restricted by the spacer 
region, producing a stable structure, the pocket region (Xiao et al. 2003; Balog et 
al. 2011), whereas the core of the amino terminus folds well with the pocket in a 
stable structure that leaves the extreme amino-terminal floppy tail, corresponding 
to the disordered region, being moved around different conformational states (Fig. 
20A). This model is the most stable conformation state for the amino terminus and 
the pocket region. However, the C-tail in the RB-prerefine model might not be 
accurate and represents only the unfolded centroid state with minimal clashes with 
the protein core. This model may not be accurate because I-Tasser software 
lacked the computational capacity to precisely model the disordered c-terminal big 
tail in the context of the full-length protein.  
To do a correct folding of the carboxyl terminus, we submitted the Fasta 
sequence corresponding to the B domain and the carboxyl terminus of pRB 
(Uniprot ID P06400, residues 640-928) to the local implementation of I-Tasser 
suite v4.4 for modeling with threading/homology to generate more than 20.000 
models. The model with the best structural alignment with the structure of the B 
domain, less clashes with the backbone and minor energy was selected, the B-
Ctail (Fig. 20C).  
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Figure 20. In silico model of human Retinoblastoma protein. (A) 3D view (cartoon 
representation) of the RB-prerefine model. (B) Disopred output plot showing the predicted 
disordered state (blue) and protein binding profile (orange) for amino acid positions of 
human pRB. Dashed line shows the score threshold. (C) 3D view (cartoon representation) 
of the model of the B-Ctail. (D) Cartoon representation and (E, front view; F, back view) 
surface representation of the refined in-silico 3D model of human pRB. (G) Zoom view of 
the surface representation of the pRB pocket. K530 and R798 are colored in white and 
orange, respectively. (E-G) Colors show domains: amino terminus, grey; A-domain, green; 
spacer, yellow sand; B-domain, red; carboxyl terminus, magenta. 
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We replaced B and C domains of the RB-prerefine model with the B-Ctail to 
generate a model with the N and A domains of RB-prerefine and the B and C 
domains of RB-B-Ctail. We used this new model as template and gaps were 
closed using the loopmodel tool (Mandell et al. 2009; Stein and Kortemme 2013) of 
Rosetta suite v3.5 release 2015.38.58158 (www.rosettacommons.org). The model 
with less score, but high energy yet, was selected as final template for refinement 
using the relax tool (Nivon et al. 2013; Conway et al. 2014) of Rosetta suite v3.5 
release 2015.38.58158 (www.rosettacommons.org).  
We finally selected the model with minor energy and correct global topology: 
correct alignment with the reference pocket structure (pdb ID: 4eljA), compatible 
with known post translational modifications and binding sites (exposed residues) 
for human pRB-associated proteins previously shown in bibliography (Fig. 20D-
20F). Since the amino and the carboxyl terminus are disordered regions, this 
model represents the most stable conformational state of the protein. A close 
inspection of this model revealed the presence of an amino-acid from the carboxyl 
terminus, R798, at the bottom surface of the pocket in close proximity to K530 (Fig. 
20G). This observation might therefore represent an important evidence of the 
structural integration of the small pocket and the carboxyl terminus to form the 
large pocket. 
 
6.3. How a point mutation could affect the protein conformation: study of 
two human patients’ mutants, RB 661W and RB 567L 
Since RB R661W and RB S567L were partially or completely inactive in cell 
growth and cell death inhibition (Fig. 12), we hypothesized that the structure of 
these mutants may be different from that of wt pRB. We therefore generated a 3D 
model of these mutants by submitting Fasta sequences of human pRB protein with 
the mutated residues (R661W or S567L) to a local implementation of I-Tasser 
software suite v5.0 (Yang et al. 2015) for modeling with homology to the previously 
modeled wt pRB. For each one, the best model with minimal energy and correct 
folding (best structural alignment to template) was selected as final template for 
refinement using the relax tool of Rosetta suite v3.6 to obtain the final models, 
pRB_R661W.pdb and pRB_S567L.pdb (Fig. 21). 
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Figure 21. Mutants RB R661W and RB S567L show major structural alterations of the 
carboxyl terminus and only minor changes in the pocket. (A) Vacuum electrostatic 
surface representation and (B) surface representation of the front and back views of 3D in-
silico model of human wt pRB and mutants RB R661W and RB S567L. (B) Colors show 
domains: amino terminus, grey; A-domain, green; spacer, yellow sand; B-domain, red; 
carboxyl terminus, magenta. Black arrows indicate the pore; blue arrows indicate the 
pocket; white arrows indicate the cleft between the amino terminus and the carboxyl 
terminus. 
 
We found that the global topology of both mutants was similar to that of wt 
pRB, showing a global Root-mean-square deviation of atomic positions (RMSD) of 
1.27Å for R661W and 1,29Å for S567L relative to wt pRB. Both mutants showed a 
destabilizing effect, that was higher in R661W (ddG of -1,15 kcal/mol) than in 
S567L (-0,22 kcal/mol), as calculated with the STRUM pipeline (Mandell et al. 
  Results 
 
 79 
2009), likely because the bigger impact of the amino-acid change (from polar 
charged positively to big hydrophobic aromatic in R661W vs small polar to small 
hydrophobic in S567L). These mutations produce a conformational change in the 
side chains accompanied by a modest reorganization of the surface electrostatic 
potential in the pocket domain and slightly more substantial around the pore and 
the carboxyl terminus (Fig. 21A). While the pore and the cleft between the amino 
terminus and the carboxyl terminus are more closed in both mutants, the pocket 
shows only minor structural changes in both mutants relative to wt pRB (Fig. 21B). 
However, we observed substantial conformational changes in the carboxyl 
terminus of RB S567L relative to wt pRB and only a modest modification in RB 
R661W (Fig. 21B). Together these data show that inactivating mutations in the A 
or in the B domain of the pocket affect only minimally the pocket conformation but 
disturb substantially the conformation of the carboxyl terminus. These data further 
support the notion that the small pocket and the carboxyl terminus are structurally 
interconnected. 
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The Retinoblastoma protein can be considered as a prototype of tumor 
suppressor protein, both for the recessive nature of the mutations in the RB1 gene and 
for the high frequency of pRB inactivation found in different types of human cancers. 
pRB is a key regulator of G1-to-S transition of the cell cycle, it is involved in 
transcription regulation, in chromatin remodeling and it takes part in G1 checkpoint 
regulation. pRB acts in different cellular processes, like differentiation, senescence, 
DNA replication and cell death (Dyson 1998; Classon and Harlow 2002; Chau and 
Wang 2003; Cobrinik 2005; Giacinti and Giordano 2006; Goodrich 2006; Henley and 
Dick 2012; Dick and Rubin 2013; Indovina et al. 2015; Dyson 2016). However, it was 
(and it is) difficult to describe a precise molecular mechanism by which pRB operates. 
Retinoblastoma protein was classified by Hasan and colleagues as a “party hub” 
protein: a protein that can act in different cellular processes and interact simultaneously 
with different partners at the same time and space (Hasan et al. 2013). Not by chance, 
according to current interaction databases (European Bioinformatics Institute [EBI]- 
IntAct, Molecular Interaction [MINT], Interologous Interaction Database [I2D], and 
String) (Morris and Dyson 2001; Dyson 2016), it was suggested that pRB can interact 
with more than 300 different proteins. Indeed, since 1998 Lee and coworkers 
suggested that pRB can simultaneously bind to more than one target, but they also 
hinted that an optimal conformation of the protein is necessary for the optimal 
performance of its different cellular processes (Lee et al. 1998). 
However, one of the most critical issues in the field of Retinoblastoma protein’s 
research is that “different groups have focused on different partners of pRB, and very 
few of the reported interactions have been confirmed by independent studies”, as 
reported by Nicholas J. Dyson on its recent review (Dyson 2016). 
The lack of an exact molecular mechanism, the difficulties of a 
proteomic/interactomic study and the consequent observation that it is easier to 
describe pRB functions in general terms rather than in specific details, prompted us to 
start a global and systematic study of this protein, focusing on cell growth and cell 
death regulation. 
 
1. RB pathway in cancer therapy 
The heterogeneity of human cancer makes nearly impossible the development of 
a general therapy. In the last years, the cell cycle machinery and particularly the RB 
pathway have become important targets for the design of specific/personalized 
molecular cancer therapies (Knudsen and Wang 2010). However, the difficulty in 
understanding the specific characteristics and alterations of each cancer case, have 
Discussion   
 
 84
caused that cytotoxic chemotherapeutic agents and ionizing radiation are still the most 
common therapeutic approaches in cancer. 
The RB pathway has been found highly compromised in a great number of 
different human cancers. Loss of the RB1 gene, epigenetic modification that cause the 
loss of p16INK4 expression and the consequent gain of function of Cyclin D-dependent 
CDKs and pRB hyperphosphorylation/inactivation, are only some of the alterations of 
the RB pathway found in human cancer. Very promising results were obtained using 
specific cell cycle inhibitors that act directly on this pathway. These specific inhibitors 
(some of them in clinical trials) recover a correct cell cycle control and increase the 
susceptibility of cancer cells to apoptosis, over all if combined with conventional 
therapy (Senderowicz 2002; Schwartz and Shah 2005; Dickson and Schwartz 2009; 
Diaz-Moralli et al. 2013). 
However, even if a specific cancer therapy could be very effective against a 
specific cancer, if a single cancer cell is able to arrest its cell cycle and activate survival 
programs, the process of cancer formation might restart. This is a critical issue in the 
context of cancer relapse that requires additional research to better understand this 
process and to improve cancer therapy. 
 
2. The importance of the “context specificity” in the inhibition of cell death 
mediated by Retinoblastoma protein 
The role of Retinoblastoma protein in the inhibition of cell death is still a 
controversial issue (Indovina et al. 2015). The first reports about the function of pRB in 
this cellular process showed an anti-apoptotic function of the protein. The huge 
extension of apoptosis detected in Rb1-/- mice during embryogenesis (Clarke et al. 
1992; Jacks et al. 1992; Lee et al. 1992; Chau and Wang 2003) or the anti-apoptotic 
effect of the exogenous expression of pRB in irradiated cells (Haas-Kogan et al. 1995), 
were a convincing indication of a protective role of Retinoblastoma protein. In contrast, 
it was suggested a function of pRB in the induction of apoptosis (Hsieh et al. 1999; De 
Leon et al. 2008; Ianari et al. 2009; Hilgendorf et al. 2013; Antonucci et al. 2014) and, 
to complicate more the situation, it was also proposed that pRB could perform both an 
anti- and a pro-apoptotic function, depending on the cellular context and the stimuli to 
which cells are subjected (Bosco and Knudsen 2005; Masselli and Wang 2006). 
The context specificity could be also the explanation of why different pRB-
interacting proteins or molecular mechanisms proposed to demonstrate pRB role in cell 
death regulation, have not been confirmed by independent studies (Dyson 2016). 
Indeed, we have found that RB ΔS, described as a mutant unable to inhibit the specific 
pro-apoptotic function of E2F1 (Julian et al. 2008), inhibited cell death induced by 
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ionizing radiation as efficiently as the wild-type protein, suggesting that pRB inhibition 
of IR-induced cell death is independent of its binding to E2F1 through the carboxyl 
terminus of pRB. In the reports that described the E2F1-specific binding site at the 
carboxyl terminus of pRB (Dick and Dyson 2003; Julian et al. 2008), C33A cells were 
used, instead of Saos2 cells, and cell death was induced over-expressing E2F1, the 
only E2F family member with pro-apoptotic function (DeGregori et al. 1997), instead of 
ionizing radiation. The specific interaction between pRB and E2F1 is regulated by DNA 
damage-dependent acetylation of pRB in K873/874 (Markham et al. 2006), suggesting 
the possibility that this post-translational modification is not active in irradiated Saos2 
cells. 
According to Janicke and colleagues, the mutant RB ΔI should be highly prone to 
degradation in a situation of DNA damage, because the caspase-specific cleavage of 
the last 42 amino acids (corresponding to the amino acids loss in mutant RB ΔI) was 
described as the first step for the full degradation of pRB (Janicke et al. 1996). It was 
suggested that the degradation of pRB caused the loss of its interaction with HDM2, 
HMD2 proteolysis and, consequently, the increase of p53 levels (Janicke et al. 1996). 
Accordingly, pRB full degradation was considered as a necessary step to avoid the 
activation of its anti-apoptotic function. In marked contrast, pRB was shown to form a 
trimeric complex with HDM2 and p53 to inhibit HDM2 activity and stabilize p53, 
suggesting a pro-apoptotic p53-dependent function of the Retinoblastoma protein 
(Hsieh et al. 1999). Finally, our data suggest that HDM2 interaction is not relevant for 
cell death inhibition in irradiated cells because the exogenous expression of RB ΔI in 
irradiated Saos2 cells protected them from nuclei fragmentation as efficiently as the 
wild-type protein. Furthermore, previous data of the laboratory could not confirm the 
interaction between ectopically expressed pRB and endogenous HDM2 in Saos2 cells 
(data not show).  
Another point of debate is the possible interaction between pRB and the 
oncoprotein c-Abl, an interaction that has been reported only by the group of Jean 
Wang (Welch and Wang 1993; Welch and Wang 1995b; Welch and Wang 1995a; 
Wang 2000). They suggested that this interaction inhibited c-Abl kinase activity and 
therefore its capacity to induce proliferation and/or apoptosis. However, previous 
experiments in our laboratory could not detect the interaction of over-expressed pRB 
with endogenous c-Abl in Saos2 cells (data not show), and pRB mutant RB 13S, 
described as a mutant that loss the capacity to interact with c-Abl and therefore to 
inhibit its pro-apoptotic capacity (Whitaker et al. 1998), inhibited IR-induced cell death 
as efficiently as wt pRB. 
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The Retinoblastoma protein has also been shown to form a ternary complex with 
BRCA1 and type II topoisomerases β (TOPO2), in Mouse Embryonic Fibroblasts, to 
repair Etoposide-induced DNA damage (Xiao and Goodrich 2005). However, we could 
not detect the association of ectopically expressed pRB with endogenous BRCA1 or 
TOPO2 in control- or in IR-treated Saos2 cells (data not show).  
It is also possible that the interaction reported between pRB and BRG1 (Khavari 
et al. 1993) is not necessary for the induction of cell cycle arrest or cell death inhibition 
in Saos2 cells. It is important to note, however, that we have not confirmed the 
dominant negative effect of the mutant BRG1-DN in Saos2 cells.  
Hilgendorf and co-workers, using MEFs, have proposed recently that pRB 
induces apoptosis directly at the mitochondria, in a Bax-dependent way (Hilgendorf et 
al. 2013). The phosphorylation of pRB Serine 807 is required for this interaction 
(Antonucci et al. 2014), but in the phospho-defective mutant of pRB (RB NPC), this 
Serine is one of the residues substituted by Alanine. Since RB NPC inhibited cell death 
induced by ionizing radiation in Saos2 cells, it seems that pRB does not induce Bax-
dependent apoptosis at the mitochondria in this specific setting. 
Finally, several reports have proposed molecular mechanisms of how pRB 
regulates cell death depending on its phosphorylation state (Adegbola and Pasternack 
2005; De Leon et al. 2008; Lentine et al. 2012; Antonucci et al. 2014). However, most 
of the phospho residues identified in these studies have been substituted by Alanine in 
the phospho-defective mutant RB NPC. For this reason, we propose that the inhibition 
of cell death by pRB is not regulated by CDK-mediated phosphorylation. 
In conclusion, the context specificity and/or the different types of DNA insults 
received by cells may influence the different mechanisms of action by which 
Retinoblastoma protein regulates cell death. Accordingly, it is possible that pRB does 
not use a general mechanism, but, depending on the cellular context and/or the type of 
DNA damage, it can interact with different partners and activate/inhibit different 
pathways, with the final goal to properly regulate cell death in a positive or in a 
negative manner. 
 
3. A new perspective of cell death inhibition induced by Retinoblastoma 
protein: what if pRB does not have a direct role in the regulation of cell 
death? 
An important finding that we introduce with this work concerns the unique 
capacity of pRB, relative to the other two members of the Retinoblastoma family, to 
inhibit both cell growth and cell death. It is particularly interesting that p107, p130 and, 
above all, the carboxyl terminal fragments of pRB (RB SE and RB C-ter) inhibit cell 
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proliferation, accumulate cells in G1, and inhibit E2F transcriptional activity, but fail to 
inhibit IR-induced cell death. Furthermore, the capacity of the carboxyl terminal domain 
of pRB to inhibit cell growth but not cell death, suggests that pRB may use different 
mechanisms of action in these two cellular processes. 
We have highlighted above the difficulties to identify a specific molecular 
mechanism by which pRB could regulate cell death. We have emphasized the 
relevance of the cellular context and the type of DNA damage, and we proposed a 
model that focused the attention on the appropriate folding of the large pocket to form a 
domain that allows pRB to perform its cellular functions. 
But, what if the situation was “easier” than we anticipated? 
When we analyzed the cell cycle profiles of non-irradiated cells 5 days after 
transfection, we observed that pRB maintained the inhibition of cell cycle progression, 
whereas p107, p130, RB SE and RB C-ter failed to maintain the accumulation of cells 
in G1. A possible explanation of these results could be that pRB may be the only of 
these proteins able to permanently inhibit E2F activity, and that the capacity to 
permanently arrest the cell cycle in G0/G1 is a specific feature of pRB, and not of other 
proteins with a role in regulation of cell cycle progression, including p27 or p21. 
Therefore, what if the function of pRB in a context of cell death is “only” to 
sustainably arrest the cell cycle and, consequently, to allow the correct activation of the 
DNA damage response? Under this perspective, pRB would not use different 
molecular mechanisms to induce growth suppression and to inhibit cell death, and the 
failure of RB SE, RB C-ter, p107 and p130 to inhibit cell death would be the 
consequence of their failure to induce a sustained arrest of the cell cycle. The short-
term effects on cell cycle progression observed with these proteins could be a 
temporary effect due to their overexpression or to the capacity of these proteins to 
delay cell cycle progression, but not to arrest it (Whitaker et al. 1998; Chung et al. 
2002). 
Although great efforts have been made to identify the molecular mechanisms of 
cell death inhibition by pRB, it might be possible that this protein has the fundamental 
function of long-term inhibition of the cell cycle, until the DNA injury is solved. We 
cannot anticipate if pRB could have a direct role in DDR activation or if the long-term 
G1 arrest is sufficient to allow DNA repair. At least in IR-treated Saos2 cells, it seems 
that pRB inhibits cell death by the induction of a long-term arrest of the cell cycle in 
G0/G1. Accordingly, a permanent G0/G1 cell cycle arrest induced by treatment with 
Mimosine, HU or CHX inhibited IR-induced cell death. Obviously, these treatments are 
toxic by themselves and increase cell death independently of ionizing radiation, but the 
cells that survived these treatments were permanently arrested in G0/G1 and resistant 
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to IR-induced cell death. Together, these data strongly suggest that a long-term G0/G1 
arrest of the cell cycle is a necessary and sufficient condition to resist cell death 
induced by IR. In fact, during DNA damage response (DDR), the activation of 
checkpoints avoids the progression to the next phase of the cell cycle, allowing the 
action of the DNA repair system and therefore preventing DNA mutation, which could 
lead to cellular transformation (Weinert 1998a; Weinert 1998b; Nyberg et al. 2002; 
Sancar et al. 2004). 
 
4. Importance of the integrity of the pRB large pocket in cell death inhibition  
Retinoblastoma protein is a member of a family of three proteins. Together with 
p107 and p130, they represent the most important proteins involved in the regulation of 
cell cycle progression (Cobrinik 2005; Henley and Dick 2012). Although these proteins 
share cellular functions and, in some cases, overlapping roles (Cobrinik et al. 1996; 
Lee et al. 1996; Classon et al. 2000; Sage et al. 2000), it is interesting that pRB is the 
only family member able to inhibit both cell cycle progression and cell death. Even if 
p107 and p130 inhibited proliferation, accumulated cells in the G1 phase of the cell 
cycle and inhibited E2F transcriptional activity, they could not avoid nuclei 
fragmentation following ionizing radiation. This is of particular interest because the 
three members of the Retinoblastoma family show a high structural homology. 
Once confirmed that cell death’s inhibition mediated by pRB was not regulated by 
Cyclin/CDKs phosphorylation in Saos2 cells, we performed a global and systematic 
study of the different domains of the protein, assessing the role of the amino terminus, 
the small pocket, the carboxyl terminus and the large pocket in growth suppression and 
cell death inhibition, and investigating if there is a correlation or a separation of these 
functions of pRB. 
According to Xu and colleagues (Xu et al. 1994), we observed that an amino-
terminal truncated mutant of pRB (RB 379-928) acts as the wild-type protein both in 
cell growth suppression and in cell death inhibition following ionizing radiation, 
suggesting that the amino terminus is not necessary for pRB functions in these cellular 
processes. 
On the other hand, a mutant lacking the carboxyl terminus of pRB (RB 1-792) 
was a non-functional protein, at least regarding the functions that we analyzed. Since a 
bipartite nuclear localization signal (NLS) was described in the carboxyl terminus of 
Retinoblastoma protein (Zacksenhaus et al. 1993), we tried to enrich the presence of 
this mutant in the nuclear fraction, cloning the NLS of SV40 large tumor antigen 
(Kalderon et al. 1984) in its amino terminus. However, we did not observe any 
substantial effect in cell growth suppression or in cell death inhibition, suggesting that 
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the loss of the ability of pRB to translocate to the nucleus is not the cause of pRB 
inactivation in the absence of its carboxyl terminus. 
These observations led us to investigate the effects of the overexpression of 
fragments corresponding to the carboxyl terminal domain of pRB (RB SE and RB C-
ter). Although RB SE and RB C-ter induced cell growth suppression, these mutants did 
not inhibit cell death following ionizing radiation. Therefore, we concluded that the 
carboxyl terminus of pRB is necessary and sufficient to inhibit cell cycle progression in 
the short-term; and necessary, but not sufficient, to inhibit cell death following ionizing 
radiation.  
The results commentated above could be a consequence of the different capacity 
of these mutants to interact with some important protein/s that allow cell growth 
suppression and/or cell death inhibition. The carboxyl terminal domain of pRB, might 
be fundamental to achieve the correct conformation of the large pocket, the minimum 
region of pRB able to both inhibit cell growth and cell death. Since the carboxyl 
terminus of pRB presents significant differences with respect to p107 and p130 (Hasan 
et al. 2013), we substituted the carboxyl terminus of p130 with the one of pRB and vice 
versa, to study if there is a gain or a loss of function, respectively, in the context of cell 
death inhibition. Although we could demonstrate the loss of function of the chimera 
pRB/p130, the chimera p130/pRB did not inhibit cell death. These data suggested that 
the carboxyl terminus of pRB has a specific structure sufficient to perform the function 
in growth suppression, but only its correct integration into the large pocket, and its 
consequent correct interaction with specific interactor/s, allows the protein to inhibit cell 
death. 
In fact, we have shown that perturbation of the small pocket affects the regulation 
of E2F activity by pRB, supporting the notion that the small pocket is critical for pRB 
functions. The substitution of residues in pRB that are highly conserved in p107 and 
p130 with the flexible linker’s sequence NAAIRS, allowed us to study different mutants 
and to identify three groups of them, according to their effect relative to wt pRB. RB 
Δ503, RB Δ529 and RB Δ685 acted as the wild-type protein, whereas RB Δ657 and 
RB Δ678 lost functions of cell growth suppression and cell death inhibition. 
Interestingly, we identified a third group of mutants that share functions with wt pRB but 
could not reach its levels of activity (RB Δ535, RB Δ542 and RB Δ651). Differences in 
activity of these mutants could be explained by substantial modification of their 
conformation as a consequence of the substitution of six amino acids with the flexible 
linker (NAAIRS); the different ability of these mutants to interact with specific 
interactor/s, allowing pRB to perform its function as growth suppressor protein and/or 
as a protein with anti-cell death activity, could be attributed to these conformational 
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modifications. Together, our data emphasize the importance of the integrity of the large 
pocket for pRB biological functions. 
 
5. An appropriate conformation of the large pocket is necessary for cell death 
inhibition mediated by the Retinoblastoma protein 
Another difficulty in the study of Retinoblastoma protein is the absence of the full-
length structure of the protein: the crystal structures available correspond to single 
domains of the protein interacting with specific partners (Xiao et al. 2003; Rubin et al. 
2005). Our in-silico analysis of the full-length sequence of pRB revealed a highly 
disorder protein that may recruit the different interacting proteins, required for the 
specific function that pRB has to perform. The carboxyl terminus might be the “binder”, 
but pRB could perform its function of “activator/inhibitor” only when its large pocket is 
folded in a precise conformation. 
Thus, in a hypothetical mechanism of action, pRB interacts with a specific 
partner/s through its carboxyl terminal domain. Once established the interaction, the 
partner/s is/are brought into the pocket, which can accommodate proteins of different 
sizes due to its plasticity; in this way, pRB could activate or inactivate this/these 
protein/s and perform properly its biological functions. 
This hypothesis could explain why the loss of the carboxyl terminus, the 
presence of only this domain, or the mutation of the small pocket, all failed to inhibit cell 
death. In fact, the in-silico model of two mutants found in patients, RB 661W and RB 
567L, showed important changes in the conformation of the protein that affected more 
severely the carboxyl terminus than the pocket. 
We proposed several models by which pRB may carry out its role in cell death 
regulation. In the first model, pRB needs a specific conformation of its large pocket for 
the correct interaction with partner X. In the second model, this protein X interacts with 
pRB through both the small pocket and the carboxyl terminus. In both models, this 
interaction could be necessary to activate the anti-cell growth or anti-cell death activity 
of this protein X or, alternatively, to inhibit its pro-cell growth or pro-cell death activity. 
Models 3 and 4 contemplated the possibility that pRB interacts with two different 
proteins wither in an independent way (protein X interacts through the small pocket and 
protein Y through the carboxyl terminus) or in a dependent way, acting as a scaffold for 
the interaction between protein X and protein Y, to form a specific ternary complex. 
Once again, these interactions could be necessary to activate the anti-cell growth or 
anti-cell death function of protein X and protein Y or those of the ternary complex. 
Alternatively, these interactions could inhibit the pro-cell growth or pro-cell death 
activity of them. 
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The overexpression of an excess of mutant RB 1-792 or of fragments 
corresponding to the carboxyl terminus of pRB (RB SE or RB C-ter) did not interfere 
with the capacity of the wild-type protein to inhibit cell growth and cell death. These 
results suggested that none of these fragments competed with full-length pRB for the 
interaction with partner/s (protein X and/or protein Y), excluding models 2 and 4.  
We also performed complementation experiments to investigate if the small 
pocket and the carboxyl terminal domain are independent units of the protein or if the 
integrity of the large pocket is necessary for pRB biological functions. Thus, the 
presence in the cells of both domains separated did not inhibit cell death following 
irradiation, excluding model 3. Together, these data strongly suggest that the small 
pocket and the carboxyl terminus of pRB have to be physically linked, as they are in 
the large pocket, to adequately expose a domain of interaction with its specific 
partner/s and to operate in cell growth suppression and in cell death inhibition. 
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The conclusions obtained with this thesis were the following: 
 
1- pRB is the only pocket family member that possesses the capacity to inhibit cell 
death in a situation of DNA damage. 
2- The inhibition of cell death by pRB is not regulated by CDK-mediated 
phosphorylation. 
3- pRB function in cell growth suppression and cell death inhibition is not mediated 
by BRG1. 
4- While the amino terminus of pRB is not required for the regulation of cell cycle 
progression and cell death inhibition, the carboxyl terminus is sufficient to block 
E2F activity and to inhibit cell cycle progression. Moreover, the carboxyl 
terminus of pRB is necessary, but not sufficient, to inhibit IR-induced cell death.  
5- pRB carboxyl terminus plays a critical role in cell growth and cell death 
inhibition regardless its contribution to the preferential location of pRB in the 
nucleus. 
6- pRB cell growth and cell death inhibitory activities are mediated by a very 
precise spatial configuration of the small pocket and the carboxyl terminus. 
7- The association of pRB C-terminal with E2F1, c-Abl, or HDM2 does not mediate 
cell death inhibition and cell growth inhibition capacities of pRB. 
8- The small pocket of pRB is required for cell death inhibition. 
9- A permanent arrest in the G1 phase of the cell cycle is necessary and sufficient 
to inhibit IR-induced cell death and only pRB arrests cell cycle in G0/G1 in a 
long-term manner, probably due to its ability to permanently inhibit E2F activity. 
The capacity to permanently arrest the cell cycle in G0/G1 is a specific feature 
of pRB, and not of other proteins with a role in regulation of cell cycle 
progression, including p27 or p21. 
10- The small pocket and the carboxyl terminus of pRB are structurally integrated to 
create a specific domain required for cell death inhibition. 
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Las conclusiones que se obtuvieron en esta tesis son: 
 
1- pRB es el único miembro de la familia Retinoblastoma que posee la capacidad 
de inhibir la muerte celular en una situación de daño al ADN. 
2- La inhibición de la muerte celular por pRB no está regulada por la fosforilación 
mediada por las quinasas dependientes de ciclinas. 
3- La función de pRB en la supresión del crecimiento celular y la inhibición de la 
muerte celular no está mediada por BRG1. 
4- El dominio amino terminal de pRB no es necesario para inhibir la progresión del 
ciclo celular y la muerte celular, mientras que el extremo carboxilo es suficiente 
para bloquear la actividad de E2F e inhibir la progresión del ciclo celular. 
Además, el carboxilo terminal de pRB es necesario, pero no suficiente, para 
inhibir la muerte celular inducida por radiación ionizante. 
5- El dominio carboxilo terminal de pRB es esencial para inhibir el crecimiento 
celular y la muerte celular independientemente de su contribución a la 
ubicación preferencial de pRB en el núcleo. 
6- La asociación del dominio carboxilo terminal de pRB con E2F1, c-Abl, o HDM2 
no media la capacidad de pRB de inhibir el crecimiento y la muerte celular. 
7- El bolsillo pequeño de pRB es necesario para inhibir la muerte celular. 
8- La inhibición de la progresión del ciclo celular y de la muerte celular están 
mediadas por una configuración espacial muy precisa del bolsillo pequeño y 
del extremo carboxilo de pRB. 
9- Una detención sostenida en la fase G1 del ciclo celular es necesaria y 
suficiente para inhibir la muerte celular inducida por radiación ionizante y sólo 
pRB detiene el ciclo celular en G0/G1 a largo plazo, probablemente debido a 
su capacidad de inhibir sostenidamente la actividad de E2F. La capacidad de 
detener sostenidamente el ciclo celular en G0/G1 es una característica 
específica de pRB, y no de otras proteínas con un papel en la regulación de la 
progresión del ciclo celular, como p27 o p21. 
10- El bolsillo pequeño y el extremo carboxilo de pRB se integran estructuralmente 
para crear un dominio específico requerido para la inhibición de la muerte 
celular. 
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